Original Article
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
N Engl J Med 2006; 355:983-991September 7, 2006
- Abstract
Background
Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non–small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy.
Methods
We used immunohistochemical analysis to determine the expression of the excision repair cross-complementation group 1 (ERCC1) protein in operative specimens of non–small-cell lung cancer. The patients had been enrolled in the International Adjuvant Lung Cancer Trial, thereby allowing a comparison of the effect of adjuvant cisplatin-based chemotherapy on survival, according to ERCC1 expression. Overall survival was analyzed with a Cox model adjusted for clinical and pathological factors.
Results
Among 761 tumors, ERCC1 expression was positive in 335 (44%) and negative in 426 (56%). A benefit from cisplatin-based adjuvant chemotherapy was associated with the absence of ERCC1 (test for interaction, P=0.009). Adjuvant chemotherapy, as compared with observation, significantly prolonged survival among patients with ERCC1-negative tumors (adjusted hazard ratio for death, 0.65; 95% confidence interval [CI], 0.50 to 0.86; P=0.002) but not among patients with ERCC1-positive tumors (adjusted hazard ratio for death, 1.14; 95% CI, 0.84 to 1.55; P=0.40). Among patients who did not receive adjuvant chemotherapy, those with ERCC1-positive tumors survived longer than those with ERCC1-negative tumors (adjusted hazard ratio for death, 0.66; 95% CI, 0.49 to 0.90; P=0.009).
Conclusions
Patients with completely resected non–small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not.
Media in This Article
Figure 1
An ERCC1-Positive Squamous-Cell Carcinoma (Panel A) and an ERCC1-Negative Squamous-Cell Carcinoma (Panel B).Figure 2
Kaplan–Meier Estimates of the Probability of Survival.Article Activity
- Article
Lung cancer is a leading cause of death from cancer in most industrialized countries.1 Despite undergoing complete resection of non–small-cell lung cancer, 33% of patients with pathological stage IA die within 5 years, as do 77% of those with pathological stage IIIA.2 Clinical trials have tested the ability of adjuvant chemotherapy to improve survival after complete resection of non–small-cell lung cancer. The International Adjuvant Lung Cancer Trial (IALT) demonstrated an absolute benefit of 4.1% in 5-year overall survival among 1867 patients who were treated with adjuvant cisplatin-based chemotherapy.3 Several other randomized studies have confirmed the benefit of postoperative platinum-based therapy in non–small-cell lung cancer.4-7 However, adjuvant chemotherapy has only a modest effect in prolonging survival, with an absolute improvement in 5-year overall survival ranging from 4 to 15%, whereas such treatment is associated with serious adverse effects.4-7 The main objective of our study, which was termed the IALT Biology (IALT Bio) study, was to identify factors that can predict a benefit from adjuvant cisplatin-based chemotherapy.
DNA repair mechanisms are important in the resistance to cisplatin. The destruction of cells by cisplatin requires the binding of the drug to DNA and the creation of platinum–DNA adducts. Some of these adducts establish covalent cross-linking between DNA strands, thereby inhibiting DNA replication. Nucleotide excision repair has a central role in DNA repair and is associated with resistance to platinum-based chemotherapy.8 The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway that recognizes and removes cisplatin-induced DNA adducts.9-11 ERCC1 is also important in the repair of interstrand cross-links in DNA and in recombination processes.12-14 In vitro studies have linked platinum resistance to the expression of ERCC1 messenger RNA (mRNA) in cell lines involved in ovarian, cervical, testicular, bladder, and non–small-cell lung cancers.15 The relation between the expression of ERCC1 mRNA and resistance to platinum compounds has been corroborated by small, retrospective clinical studies in patients with advanced gastric, ovarian, colorectal, esophageal, or non–small-cell lung cancer.15-25 These data led us to hypothesize that expression of ERCC1 by the tumor could predict a survival benefit from cisplatin-based adjuvant chemotherapy in non–small-cell lung cancer.
Methods
Patients and Study Design
All patients had participated in the IALT, which compared adjuvant cisplatin-based chemotherapy with observation among patients with non–small-cell lung cancer. Inclusion criteria and the results of the IALT have been reported previously.3 In brief, we randomly assigned 1867 patients with completely resected non–small-cell lung cancer in stages I through III to receive either cisplatin (at a total dose of 300 to 400 mg per square meter of body-surface area) plus an additional drug (etoposide or a vinca alkaloid) or to be observed only (the control group). The median follow-up was 56 months.
The IALT Bio study was subsequently designed by a steering committee to examine whether tumor markers assessed by immunohistochemical analysis could be used to predict a survival benefit from chemotherapy. The study was conducted according to a detailed protocol and monitored by the steering committee. The protocol stressed the importance of collecting all samples within the participating centers, required a large number of tumor samples to ensure adequate power for prognostic and predictive analyses, and imposed a plan for statistical analysis. To study whether the effect of chemotherapy varied between patients with a positive marker and an equal number of patients with a negative marker, the estimated power to detect a 20% difference in the survival benefit at 5 years, given the enrollment of 800 patients, was 66% (with a two-sided alpha level of 0.01). Such a design has the ability to address the predictive value of 25 markers.
Paraffin-embedded tumor samples were collected from patients at centers that had recruited more than 10 patients. Twenty-eight centers in 14 countries contributed specimens (see the Appendix). Approval was obtained from the local institutional review boards, according to the legal regulations in each participating country. All tumors were reviewed centrally at the Centre Hospitalier Universitaire Albert Michallon, according to the histopathological classification system adopted by the World Health Organization (WHO) in 2004.26 Immunostaining was performed and evaluated at Institut Gustave Roussy. Representatives of Eli Lilly had access to an early draft of the manuscript for information but otherwise had no input into the manuscript. Members of the steering committee were responsible for the decision to publish the manuscript.
Immunostaining for ERCC1
We used a standard protocol for the immunostaining of the samples. In brief, for epitope retrieval, specimens were exposed to 10 mM citrate buffer (pH 6.0) and heated for 30 minutes in a water bath. Tumor sections were incubated for 60 minutes with a monoclonal antibody specific against the full-length human ERCC1 protein at a 1:300 dilution (mouse, clone 8F1, Neomarkers).27-30 Antibody binding was detected by means of an ABC kit with NovaRED as the substrate (Vectastain Elite, Vector Laboratories) and Mayers hematoxylin as the counterstain. Sections of normal tonsil tissues were included as external positive controls, and stromal cells surrounding the tumor area served as internal positive controls.
Microscopical Analysis
Two investigators who were unaware of clinical data independently evaluated ERCC1 staining under a light microscope at a magnification of 400×. They recorded whether tumor or stromal cells expressed ERCC1. The staining intensity was graded on a scale of 0 to 3 (with a higher number indicating a higher intensity and with endothelial cells in tonsil control tissue used as a reference and assigned an intensity of 2). Discordant cases were reviewed. Cases without valid internal controls were excluded. Five images of representative areas were acquired at a magnification of 400× for each specimen. A total of 500 to 1500 positive or negative tumor nuclei per specimen were manually counted on a computer screen with the use of ImageJ freeware from the National Institutes of Health (http://rsb.info.nih.gov/ij). The percentage of positive tumor nuclei was calculated for each specimen, and a proportion score was assigned (0 if 0%, 0.1 if 1% to 9%, 0.5 if 10% to 49%, and 1.0 if 50% or more), as previously described.31,32 This proportion score was multiplied by the staining intensity of nuclei to obtain a final semiquantitative H score. The median value of all the H scores was a priori chosen as the cutoff point for separating ERCC1-positive tumors from ERCC1-negative tumors.
Statistical Analysis
As in the IALT study, the primary end point was overall survival after randomization. Disease-free survival was analyzed as a secondary end point. To identify any selection bias within the participating centers, the baseline characteristics of the two groups of patients (with or without blocks of tumor tissue) were compared with the use of chi-square tests stratified according to center, and the overall rates of survival were compared with the use of a Cox model. Baseline data according to ERCC1 status were compared in univariate analyses with the use of chi-square tests and in a multivariate logistic model including all variables with P values of less than 0.05.
Survival rates were estimated with the use of the Kaplan–Meier method. The prognostic values of the ERCC1 status and chemotherapy were studied with the use of a Cox model, which was stratified according to center and adjusted for significant prognostic factors for survival (sex and the stage of disease) and factors associated with ERCC1 (age, revised histopathological type, and the presence or absence of pleural invasion). The predictive value of ERCC1 was studied by testing the interaction between the ERCC1 status and the attributed treatment (chemotherapy or no chemotherapy) in the same Cox model. We performed sensitivity analyses using Cox models with a variety of adjustment factors, and the results were similar. Therefore, we report only results that corresponded to the model we previously described. All reported P values are two-sided. P values of less than 0.01 were a priori considered to indicate statistical significance to limit the risk of false positive results. All analyses were performed with the use of SAS software, version 8.2 (SAS Institute).
Results
Characteristics of the Patients
As a group, the 28 centers that participated in our study were able to provide one tumor block for 867 of the 1045 patients (83%) who had enrolled in the original IALT study. These 867 patients and the remaining 178 had similar baseline characteristics and overall rates of survival. The amount and quality of 824 of the 867 blocks were adequate for serial sectioning. Among these blocks, 783 contained tumor material corresponding to non–small-cell lung cancer and were included in our study. After exclusion of blocks without valid positive internal controls, ERCC1 expression was evaluated in a total of 761 patients. All further statistical analyses were performed on this population.
Table 1Table 1
Characteristics of the Patients. summarizes the characteristics of the study population. A total of 426 patients had squamous-cell carcinomas (56%), 242 had adenocarcinomas (32%), and 93 had another histologic type (12%). The median age of the patients was 58 years (range, 27 to 77), and 82% were men. Of the 761 patients, 389 (51%) received adjuvant cisplatin-based chemotherapy and 372 (49%) were in the control group.Immunohistochemical Assessment of ERCC1 Expression
Figure 1Figure 1
An ERCC1-Positive Squamous-Cell Carcinoma (Panel A) and an ERCC1-Negative Squamous-Cell Carcinoma (Panel B). shows that ERCC1 was localized to the nucleus. The median percentage of cells with nuclei that stained with the monoclonal antibody was 24% (range, 0 to 100), whereas the median value of H scores was 1.0. Tumors with an H score exceeding 1.0 (i.e., tumors with a staining intensity score of 2 and with 50% or more positive nuclei or with a staining intensity score of 3 and 10% or more positive nuclei) were deemed to be ERCC1-positive. Of the 761 tumors, 335 (44%) were ERCC1-positive. Table 1 compares the demographic characteristics, tumor characteristics, and treatments according to ERCC1 expression in a univariate analysis. A multivariate logistic model showed that the expression of ERCC1 was significantly correlated with age (P=0.03; less common in patients younger than 55 years of age than in patients 55 to 64 years of age), histologic type (P<0.001; less common in adenocarcinomas than in squamous-cell carcinomas), and pleural invasion (P=0.01; less common in the absence than in the presence of pleural invasion).Survival and ERCC1 Expression
The 5-year overall survival rate was 43% (95% confidence interval [CI], 39% to 47%) for the total study population (Table 2Table 2
Overall Survival According to Attributed Treatment and ERCC1 Status.). In the Cox model, adjusted for the multivariate predictors of survival, ERCC1 expression, as compared with the absence of expression of ERCC1, had no prognostic value for the entire study population (adjusted hazard ratio for death, 0.88; 95% CI, 0.71 to 1.10; P=0.26).Survival and Adjuvant Chemotherapy
The 5-year overall survival rates were 44% in the chemotherapy group (95% CI, 39% to 50%) and 42% in the control group (95% CI, 37% to 48%) (Table 2). In the Cox model, the adjusted hazard ratio for death was 0.84 (95% CI, 0.68 to 1.03; P=0.09) in favor of chemotherapy (Table 2 and Figure 2AFigure 2
Kaplan–Meier Estimates of the Probability of Survival.).Survival, ERCC1 Expression, and Chemotherapy
Among patients with ERCC1-negative tumors, overall survival was significantly longer in the chemotherapy group than in the control group (adjusted hazard ratio for death, 0.65; 95% CI, 0.50 to 0.86; P=0.002) (Table 2). The 5-year overall survival rates among patients with ERCC1-negative tumors were 47% (95% CI, 40% to 55%) in the chemotherapy group and 39% (95% CI, 32% to 47%) in the control group. Median overall survival was 14 months longer in the adjuvant chemotherapy group (56 months) than in the control group (42 months) (Figure 2B). Disease-free survival among patients with ERCC1-negative tumors was also longer in the chemotherapy group than in the control group (adjusted hazard ratio for recurrence or death, 0.65; 95% CI, 0.50 to 0.85; P=0.001) (Figure 2C).
Among patients with ERCC1-positive tumors, there was no significant difference in survival between the adjuvant chemotherapy group and the control group (adjusted hazard ratio for death, 1.14; 95% CI, 0.84 to 1.55; P=0.40) (Table 2 and Figure 2D).
Overall, the interaction terms between ERCC1 expression and treatment were significant for overall survival (P=0.009) and for disease-free survival (P=0.008).
Survival and ERCC1 Expression in the Control Group
When the analysis focused exclusively on patients in the control group, the 5-year overall survival rate was significantly higher among patients with ERCC1-positive tumors (46%; 95% CI, 37% to 55%) than among patients with ERCC1-negative tumors (39%; 95% CI, 32% to 47%), with an adjusted hazard ratio of 0.66 (95% CI, 0.49 to 0.90; P=0.009) (Table 2).
Discussion
The IALT reported a benefit from adjuvant cisplatin-based chemotherapy for patients with completely resected non–small-cell lung cancer (hazard ratio for death, 0.86 in 1867 patients), but no predictor of benefit from chemotherapy was identified.3 One of the important findings in our study is that a low level of expression of ERCC1 by tumor cells was associated with longer survival after adjuvant treatment with cisplatin-based chemotherapy. In the group of patients with ERCC1-negative tumors who received such treatment, the risk of death was decreased by 35% (hazard ratio, 0.65). By contrast, the risk of death was not decreased among patients with ERCC1-positive tumors who received cisplatin-based adjuvant chemotherapy (hazard ratio, 1.14). Although it was not possible to collect tumor samples from all patients in centers that participated in our study, the baseline characteristics and survival of the 83% who were included in our study did not differ significantly from those of the 17% who were not included. Furthermore, our findings are strengthened by an adjustment for standard prognostic variables, the requirement of a high level of significance (with a two-sided alpha level of 0.01), and the definition of an a priori cutoff point for an ERCC1-positive tumor.33
ERCC1 is the limiting factor in nucleotide excision repair, which removes platinum–DNA adducts. ERCC1 may also be involved in the repair of DNA double-strand breaks, especially those induced by interstrand cross-links.12 For this reason, the mechanism by which ERCC1 contributes to cisplatin resistance probably involves more than nucleotide excision repair. It is possible that the presence of ERCC1 reflects an inherent biologic characteristic of the tumor. However, as suggested in previous studies,34 in the control group, patients who had ERCC1-negative tumors had a shorter overall survival than did patients with ERCC1-positive tumors (Table 2). This finding is in contrast to the results observed in patients who received adjuvant chemotherapy and favors the interpretation that the presence or absence of ERCC1 is a determinant of the sensitivity of non–small-cell tumor cells to platinum. Other factors may also contribute to the sensitivity to platinum (e.g., tolerance to DNA damage), and the clinical relevance of these factors may depend on the dose of cisplatin that is administered, the combination of cisplatin with other drugs, subsequent radiotherapy, and other aspects of treatment. Consequently, we cannot make a general statement concerning the influence of ERCC1 expression on the outcome of other treatment regimens for non–small-cell lung cancer.
Our results suggest that determination of ERCC1 expression in non–small-cell lung cancer cells before chemotherapy can make a contribution as an independent predictor of the effect of adjuvant chemotherapy. For more than a decade, small studies have repeatedly reported an association between low levels of expression of ERCC1 mRNA in several solid tumors and improved clinical outcomes among patients treated with platinum-containing regimens.15-18,20,21,24 In particular, it has been reported that the expression of ERCC1 mRNA predicts a response to chemotherapy in advanced non–small-cell lung cancer.20 Furthermore, two common polymorphisms of the ERCC1 gene35-38 (codon 118 C/T and C8092A) have been correlated with the response to platinum-based chemotherapy in colorectal cancer39 and non–small-cell lung cancer.40 These polymorphisms are mainly associated with lower rates of translation of the ERCC1 gene, which results in low levels of the protein in nuclei. Since the type of immunohistochemical analysis we used can be applied in almost every pathology laboratory, our findings could be widely applicable if confirmed by independent studies.
In conclusion, patients with completely resected non–small-cell lung cancer and ERCC1-negative tumors derived a substantial benefit from adjuvant cisplatin-based chemotherapy, as compared with patients with ERCC1-positive tumors.
Supported by grants from Programme Hospitalier de Recherche Clinique 2005, Cancéropôle Rhône-Alpes, the Institute of Pathology Graz, and the Center of Excellence in Clinical and Experimental Oncology at the Medical University of Vienna; a grant (P15377) from the Austrian Science Fund; and an unrestricted research grant from Eli Lilly.
No potential conflict of interest relevant to this article was reported.
We are indebted to Lorna Saint Ange for her editing assistance and to Eric Deutsch, Catherine Hill, Guido Kroemer, and Raphaël Rousseau for their critical reading of the manuscript.
Source Information
From the Laboratory of Radiobiology and Oncology, Commissariat à l'Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris (K.A.O., L.S., J.-C.S.); the Biostatistics and Epidemiology Unit (A.D., V.H., J.-P.P.) and the Departments of Pathology and Translational Research (P.F., E.T.) and Medicine (F.A., T.T., T.L.C., J.-C.S.), Institut Gustave Roussy, Villejuif; the Department of Pathology, Centre Hospitalier Universitaire Albert Michallon, Grenoble (E.B.); and the Université Pierre et Marie Curie, Paris (P.F.) — all in France; the Department of Internal Medicine, Medical University of Vienna, Vienna (M.F., R.P.); the Institute of Pathology, University Medical School of Graz, Graz, Austria (H.H.P.); and Klinik und Poliklinik für Onkologie, Universitätsspital, Zurich (R.S.).
Address reprint requests to Dr. Soria at the Department of Medicine, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif, France, or at soria@igr.fr.
Other investigators who participated in the International Adjuvant Lung Cancer Trial Biology (IALT Bio) study are listed in the Appendix.
Appendix
Members of the steering committee for the IALT Bio study were Fabrice André, Elisabeth Brambilla, Ariane Dunant, Martin Filipits, Thierry Le Chevalier, Jean-Pierre Pignon, Robert Pirker, Helmut Popper, Jean-Charles Soria, and Rolf Stahel. The following investigators and pathologists also participated in this study: Austria — R. Pirker, Internal Medicine, Vienna; G. Dekan, Institute of Pathology, Vienna; Belgium — J. Vansteenkiste, University Hospital, Leuven; Brazil — I. Sathler Pinel, Instituto Nacional de Cancer, Rio de Janeiro; R. Younes, Hospital Antonio Candido Camarco, São Paulo; France — A. Kanoui, Centre Physiothérapie du Rouget, Sarcelles; R. Dachez, Laboratoire Claude Levy, Paris; S. Deslignères, Hospital Delafontaine, Saint-Denis; O. Languille-Mimoune, Cabinet Pathologie, Paris; P. Sabatier, Centre Hospitalier Victor Dupouy, Argenteuil; T. Le Chevalier, Institut Gustave-Roussy, Villejuif; P. Boz, Cabinet de Pathologie, Papeete; P. Bruneval, Association Promotion Anatomie Pathologique, Paris; F. Capron, Groupe Hospitalier Pitié-Salpétrière, Paris; M. Charpentier, Cabinet Pathologie Tolbiac, Paris; B. Chetaille, Hôpital Sainte Marguerite, Marseille; E. Dulmet, Centre Chirurgical Marie-Lannelongue, Le Plessis Robinson; B. Gosselin, Centre Hospitalier Universitaire, Lille; D. Grunenwald, P. Validire, Institut Mutualiste Montsouris, Paris; F. Labrousse, Centre Hospitalier Universitaire, Limoges; D. Petrot, Cabinet d'Anatomie Pathologique, Niort; N. Rouyer, Cabinet de Pathologie Butet-Rouyer, Nice; B. Milleron, M. Antoine, Hôpital Tenon, Paris; J. Morère, M. Kambouchner, Hôpital Avicenne, Bobigny; G. Ozenne, Ceditrac — Centre Médico Chirurgical du Cèdre, Bois Guillaume; T. Ducastelle, Laboratoire d'Anatomie et Cytologie, Rouen; E. Quoix, Hôpital Lyautey, Strasbourg; P. Durand de Grossouvre, Laboratoire d'Anatomie Pathologique, Haguenau; B. Gasser, Centre Hospitalier Universitaire, Strasbourg; A. Rivière, Centre François Baclesse, Caen; F. Galateau-Salle, Centre Hospitalier Universitaire, Caen; C. Tuchais, P. Jallet, G. Bertrand, I. Valo, Centre Paul Papin, Angers; Germany — W. Eberhardt, University Hospital, Essen; D. Theegarten, Institute of Pathology, Ruhr-University Bochum, Bochum; Greece — P. Christaki, Papanikolaou General Hospital, Pylea; T. Dosios, V. Kyriakou, Athens University School of Medicine, Athens; E. Papadakis, P. Agelidou, Sotiria Hospital, Athens; K. Zarogoulidis, University Hospital, Thessaloniki; Italy — A. Masotti, Azienda Ospedaliera Di Verona, Verona; N. Pericoli, Ospedale Santa Maria Goretti, Latina; Lithuania — A. Jackevicius, Institute of Oncology Vilnius University, Vilnius; Poland — J. Laudanski, L. Chyczewski, M. Kozlowski, J. Niklinski, Medical School, Bialystok; T. Grodski, J. Pankowski, Regional Hospital for Lung Diseases, Szczecin; T. Orlowski, M. Chabowski, R. Langfort, Institute of Tuberculosis and Lung Disease, Warsaw; B. Muszczynska-Bernhard, Dolnoslaskiego Centrum Chorob Pluc, Wroclaw; Romania — T. Ciuleanu, Oncological Institute Ion Chiricuta, Cluj-Napoca; Slovakia — J. Baumohl, University Teaching Hospital, Kosice; Spain — F. Cardenal, Hospital Duran I Reynals, Barcelona; R. Bernat, Hospital de Bellvitge, Barcelona; J. Salinas, J.B. Lopez, Hospital Virgen de Arrixaca, El Palmar Murcia; Sweden — B. Bergman, A. Hussein, Sahlgrenska Hospital, Göteborg; Yugoslavia — G. Radosavljevic, Institute for Lung Disease, Belgrade.
- References
References
1
Jemal A ,Murray T ,Ward E , et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30[Erratum, CA Cancer J Clin 2005;55:259.]
CrossRef | Web of Science | Medline2
Mountain CF . Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717
CrossRef | Web of Science | Medline3
The International Adjuvant Lung Cancer Trial Collaborative Group
Full Text | Web of Science | Medline4
Gurubhagavatula S ,Lynch TJ . The role of adjuvant chemotherapy for non-small cell lung cancer. Semin Respir Crit Care Med 2005;26:298-303
CrossRef | Web of Science | Medline5
Winton T ,Livingston R ,Johnson D , et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597
Full Text | Web of Science | Medline6
Douillard J ,Rosell R ,Delena M ,Legroumellec A ,Torres A ,Carpagnano F . ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. J Clin Oncol 2005;23:Suppl 16:A7013-A7013 abstract.
CrossRef | Web of Science7
Strauss GM ,Herndon J ,Maddaus A , et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2004;22:Suppl 14:A7019-A70198
Reed E . Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-344
CrossRef | Web of Science | Medline9
Mu D ,Hsu DS ,Sancar A . Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996;271:8285-8294
CrossRef | Web of Science | Medline10
Sancar A . Mechanisms of DNA excision repair. Science 1994;266:1954-1956
CrossRef | Web of Science | Medline11
Zamble DB ,Mu D ,Reardon JT ,Sancar A ,Lippard SJ . Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996;35:10004-10013
CrossRef | Web of Science | Medline12
De Silva IU ,McHugh PJ ,Clingen PH ,Hartley JA . Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-7990
CrossRef | Web of Science | Medline13
Niedernhofer LJ ,Odijk H ,Budzowska M , et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-5787
CrossRef | Web of Science | Medline14
Sargent RG ,Meservy JL ,Perkins BD , et al. Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res 2000;28:3771-3778
CrossRef | Web of Science | Medline15
Altaha R ,Liang X ,Yu JJ ,Reed E . Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-970
Web of Science | Medline16
Dabholkar M ,Bostick-Bruton F ,Weber C ,Bohr VA ,Egwuagu C ,Reed E . ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-1517
CrossRef | Web of Science | Medline17
Dabholkar M ,Vionnet J ,Bostick-Bruton F ,Yu JJ ,Reed E . Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-708
CrossRef | Web of Science | Medline18
Joshi MB ,Shirota Y ,Danenberg KD , et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-2221
CrossRef | Web of Science | Medline19
Langer R ,Specht K ,Becker K , et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11:7462-7469
CrossRef | Web of Science | Medline20
Lord RV ,Brabender J ,Gandara D , et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291
Web of Science | Medline21
Metzger R ,Leichman CG ,Danenberg KD , et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316
Web of Science | Medline22
Reed E ,Dabholkar M ,Thornton K ,Thompson C ,Yu JJ ,Bostick-Bruton F . Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep 2000;7:1123-1128
Web of Science | Medline23
Rosell R ,Lord RV ,Taron M ,Reguart N . DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002;38:217-227
CrossRef | Web of Science | Medline24
Shirota Y ,Stoehlmacher J ,Brabender J , et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304
Web of Science | Medline25
Warnecke-Eberz U ,Metzger R ,Miyazono F , et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794-3799
CrossRef | Web of Science | Medline26
Brambilla E ,Lantuejoul S ,Dunant A , et al. IALT (International Adjuvant Lung Cancer Trial): quality assessment and histopathological review according to the WHO 2004 classification and assessment of prognostic and predictive role of pathological criteria. Lung Cancer 2005;49:Suppl 2:S44-S44
CrossRef | Web of Science27
Murray D ,Mirzayans R ,Scott AL ,Allalunis-Turner MJ . Influence of oxygen on the radiosensitivity of human glioma cell lines. Am J Clin Oncol 2003;26:e169-e177
CrossRef | Medline28
Nix P ,Greenman J ,Stafford N ,Cawkwell L . Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Therapy 2004;2:47-5329
Wachters FM ,Wong LS ,Timens W ,Kampinga HH ,Groen HJ . ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211-219
CrossRef | Web of Science | Medline30
Kim DY ,Cho MS ,Cho JY , et al. Significance of ercc1 protein expression in predicting response for advanced gastric cancer patients receiving cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2003;22:1079-107931
Al Haddad S ,Zhang Z ,Leygue E , et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999;155:2057-2066
CrossRef | Web of Science | Medline32
Handra-Luca A ,Bilal H ,Bertrand JC ,Fouret P . Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 2003;163:957-967
CrossRef | Web of Science | Medline33
McShane LM ,Altman DG ,Sauerbrei W ,Taube SE ,Gion M ,Clark GM . Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-9072
CrossRef | Web of Science | Medline34
Simon GR ,Sharma S ,Cantor A ,Smith P ,Bepler G . ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983
CrossRef | Web of Science | Medline35
Chen P ,Wiencke J ,Aldape K , et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000;9:843-847
Web of Science | Medline36
Park DJ ,Zhang W ,Stoehlmacher J , et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-166
Medline37
Sturgis EM ,Dahlstrom KR ,Spitz MR ,Wei Q . DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002;128:1084-1088
Web of Science | Medline38
Yu JJ ,Mu C ,Lee KB , et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20
Web of Science | Medline39
Viguier J ,Boige V ,Miquel C , et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-6217
CrossRef | Web of Science | Medline40
Zhou W ,Gurubhagavatula S ,Liu G , et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10:4939-4943
CrossRef | Web of Science | Medline
- Citing Articles (426)
Citing Articles
1
C. M. Choi, S. C. Yang, H. J. Jo, S. Y. Song, Y. J. Jeon, T. W. Jang, D. J. Kim, S. H. Jang, S. H. Yang, Y. D. Kim, K. H. Lee, S. J. Jang, Y. T. Kim, D. K. Kim, D. H. Chung, L. Kim, H. S. Nam, J. H. Cho, H. J. Kim, J. S. Ryu. (2012) Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Annals of Oncology
CrossRef2
Jingwei Jiang, Xiaohua Liang, Xinli Zhou, Ruofan Huang, Zhaohui Chu, Qiong Zhan. (2012) ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Molecular Biology Reports
CrossRef3
Liang Cheng, Riley E Alexander, Gregory T MacLennan, Oscar W Cummings, Rodolfo Montironi, Antonio Lopez-Beltran, Harvey M Cramer, Darrell D Davidson, Shaobo Zhang. (2012) Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology
CrossRef4
W. E. Pierceall, K. A. Olaussen, V. Rousseau, E. Brambilla, K. M. Sprott, F. Andre, J.- P. Pignon, T. Le Chevalier, R. Pirker, C. Jiang, M. Filipits, Y. Chen, J. L. Kutok, D. T. Weaver, B. E. Ward, J.- C. Soria. (2012) Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Annals of Oncology
CrossRef5
Dianke Yu, Juan Shi, Tong Sun, Xiaoli Du, Li Liu, Xiaojiao Zhang, Chao Lu, Xiaohu Tang, Meng Li, Lingchen Xiao, Zhouwei Zhang, Qipeng Yuan, Ming Yang. (2012) Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumor Biology
CrossRef6
Nicolas Girard. (2012) Driver mutations as predictive biomarkers in lung cancer. Current Respiratory Care Reports
CrossRef7
Atsunari Kawashima, Hitoshi Takayama, Akira Tsujimura. (2012) A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy. Advances in Urology 2012, 1-6
CrossRef8
Betty C. Tong, David H. Harpole. (2012) Molecular Markers for Incidence, Prognosis, and Response to Therapy. Surgical Oncology Clinics of North America 21:1, 161-175
CrossRef9
Corey J. Langer. (2012) Exploring biomarkers in head and neck cancer. Cancern/a-n/a
CrossRef10
Alexandra V. Lucs, Benjamin Saltman, Christine H. Chung, Bettie M. Steinberg, David L. Schwartz, Jeffrey N. Myers. (2012) Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head & Neckn/a-n/a
CrossRef11
Corey J. Langer. (2012) Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. Critical Reviews in Oncology/Hematology
CrossRef12
Audrey Mansuet-Lupo, Thierry Jo Molina, Diane Damotte. (2012) Les nouveautés dans les carcinomes broncho-pulmonaires non à petites cellules. Revue Francophone des Laboratoires 2012:438, 47-54
CrossRef13
Young-Kwang Yoon, Seock-Ah Im, Hwang-Phill Kim, Hyung-Seok Hur, Kyung-Hun Lee, Sae-Won Han, Sang-Hyun Song, Do Youn Oh, Tae-You Kim, Woo Ho Kim, Yung-Jue Bang. (2012) Sunitinib Synergizes the Antitumor Effect of Cisplatin via Modulation of ERCC1 Expression in Models of Gastric Cancer. Cancer Letters
CrossRef14
Marina Schena, Simonetta Guarrera, Lucio Buffoni, Angelica Salvadori, Floriana Voglino, Alessandra Allione, Giancarlo Pecorari, Enrico Ruffini, Paolo Garzino-Demo, Sara Bustreo, Lorena Consito, Paolo Bironzo, Giuseppe Matullo. (2012) DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair
CrossRef15
Jennifer M. Rubatt, Kathleen M. Darcy, Chunqiao Tian, Franco Muggia, Rajiv Dhir, Deborah K. Armstrong, Michael A. Bookman, Laura J. Niedernhofer, Julie Deloia, Michael Birrer, Thomas Carl Krivak. (2012) Pre-Treatment Tumor Expression of ERCC1 in Women with Advanced Stage Epithelial Ovarian Cancer is Not Predictive of Clinical Outcomes: A Gynecologic Oncology Group Study. Gynecologic Oncology
CrossRef16
John J. Turchi, Steve M. Patrick. 2012. Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications. , 109-117.
CrossRef17
Henning Willers, Heike N. Pfäffle, Lee Zou. 2012. Targeting Homologous Recombination Repair in Cancer. , 119-160.
CrossRef18
Christina Perry, Rebeka Sultana, Srinivasan Madhusudan. 2012. Personalized Cancer Medicine. , 257-282.
CrossRef19
M. Pless. (2011) Das fortgeschrittene Lungenkarzinom. Der Pneumologe
CrossRef20
E. F. Smit, M. A. Socinski, B. P. Mullaney, S. P. Myrand, G. V. Scagliotti, P. Lorigan, M. Reck, T. Ciuleanu, J. von Pawel, N. A. Karaseva, A. Szczesna, D. Ohannesian, E. Powell, R. R. Hozak, S. Hong, S. C. Guba, N. Thatcher. (2011) Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Annals of Oncology
CrossRef21
Niels Frank Jensen, David Hersi Smith, Sune Boris Nygård, Maria Unni Rømer, Kirsten Vang Nielsen, Nils Brünner. (2011) Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scandinavian Journal of Gastroenterology1-16
CrossRef22
A. Van Den Broeck, D. Nissou, E. Brambilla, B. Eymin, S. Gazzeri. (2011) Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis
CrossRef23
Martin Filipits, Robert Pirker. (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74:3, 355-363
CrossRef24
Scott Gettinger, Thomas Lynch. (2011) A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest Medicine 32:4, 839-851
CrossRef25
Laura Bonanno, Adolfo Favaretto, Massimo Rugge, Miquel Taron, Rafael Rosell. (2011) Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs 71:17, 2231-2246
CrossRef26
Yin Tian, Jun Zhang, Shuangshuang Yan, Li Qiu, Zheng Li. (2011) FATS expression is associated with cisplatin sensitivity in non small cell lung cancer. Lung Cancer
CrossRef27
Florence Cheung, Oscar Chan, Wai Tong Ng, Lucy Chan, Anne Lee, Siu Wah Pang. (2011) The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncology
CrossRef28
Benjamin Besse, David Planchard, Anne-Sophie Veillard, Laurent Taillade, David Khayat, Muriel Ducourtieux, Jean-Pierre Pignon, Jean Lumbroso, Carole Lafontaine, Claire Mathiot, Jean-Charles Soria. (2011) Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer
CrossRef29
Bartomeu Massuti, Manuel Cobo, Carlos Camps, Manuel Dómine, Mariano Provencio, Vicente Alberola, Nuria Viñolas, Rafael Rosell, Miguel Tarón, Vanesa Gutiérrez-Calderón, Pilar Lardelli, Vicente Alfaro, Antonio Nieto, Dolores Isla. (2011) Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer
CrossRef30
William E. Pierceall, Kam M. Sprott, Tuomas Heikkinen, Paivi Heikkila, Lakshmi Alaparthi, Kristiina Aittomaki, Mohammed El-Adhami, Vivian Villegas-Bergazzi, Jane L. Meyer, Jeffery L. Kutok, Jirina Bartkova, Jiri Bartek, Heli Nevanlinna, David T. Weaver, Carl Blomqvist. (2011) Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Human Pathology
CrossRef31
Lucianne Maia Costa Lima, Ludmilla Regina de Souza, Thiago Fonseca da Silva, Camila Santos Pereira, André Luiz Sena Guimarães, Alfredo Maurício Batista de Paula, Heloisa de Andrade Carvalho. (2011) DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathologyno-no
CrossRef32
Dipali Dhawan, Harish Padh. 2011. Omics Approaches in Cancer Biomarker and Targeted Anticancer Drug Discovery. , 333-358.
CrossRef33
Jian Cheng, Minwen Ha, Yadi Wang, Jing Sun, Junchen Chen, Yue Wang, Chunyan Tong. (2011) A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology
CrossRef34
Gury Doshi, Guru Sonpavde, Cora N Sternberg. (2011) Clinical and pharmacokinetic evaluation of satraplatin. Expert Opinion on Drug Metabolism & Toxicology1-9
CrossRef35
N. Reinmuth, D. Heigener, M. Reck. (2011) Behandlung des nichtkleinzelligen Lungenkarzinoms. Der Internist
CrossRef36
Po-Hui Wang, Jiunn-Liang Ko, Shun-Fa Yang, Long-Yau Lin. (2011) Implication of human nonmetastatic clone 23 Type 1 and its downstream gene lipocalin 2 in metastasis and patient's survival of cancer of uterine cervix. International Journal of Cancer 129:10, 2380-2389
CrossRef37
Julio Sánchez de Cos Escuín. (2011) Estadificación y pronóstico molecular del cáncer de pulmón. Archivos de Bronconeumología 47:11, 539-540
CrossRef38
Kiyoshi Hasegawa, Rina Kato, Yutaka Torii, Ryoko Ichikawa, Shuko Oe, Yasuhiro Udagawa. (2011) The Relationship Between ERCC1 Expression and Clinical Outcome in Patients With FIGO Stage I to Stage II Uterine Cervical Adenocarcinoma. International Journal of Gynecological Cancer 21:8, 1479-1485
CrossRef39
Richard L Schilsky. (2011) Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine 8:6, 633-640
CrossRef40
Jung-min Lee, Jasmine J. Han, Gary Altwerger, Elise C. Kohn. (2011) Proteomics and biomarkers in clinical trials for drug development. Journal of Proteomics 74:12, 2632-2641
CrossRef41
Akshay Sudhindra, Roberto Ochoa, Edgardo S. Santos. (2011) Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer 12:6, 360-368
CrossRef42
Joshua A. Roth, Josh J. Carlson. (2011) Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Lung Cancer 12:6, 393-401
CrossRef43
M. Joerger, D. deJong, A. Burylo, J.A. Burgers, P. Baas, A.D.R. Huitema, J.H. Beijnen, J.H.M. Schellens. (2011) Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy. Lung Cancer 74:2, 310-317
CrossRef44
Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances A Shepherd. (2011) Non-small-cell lung cancer. The Lancet 378:9804, 1727-1740
CrossRef45
Erdem Cubukcu, Omer Fatıh Olmez, Ozlem Saraydaroglu, Unsal Akcalı, Ozkan Kanat, Ender Kurt, Turkkan Evrensel, Osman Manavoglu. (2011) Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome. Clinical and Translational Oncology 13:11, 826-830
CrossRef46
Peter Mazzone, Tarek Mekhail. (2011) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine
CrossRef47
Julio Sánchez de Cos Escuín. (2011) Molecular Staging and Prognosis in Lung Cancer. Archivos de Bronconeumología (English Edition) 47:11, 539-540
CrossRef48
Elisa Giovannetti, Paola Pacetti, Michele Reni, Leticia G Leon, Andrea Mambrini, Enrico Vasile, Michele Ghidini, Niccola Funel, Matteo Lucchesi, Stefano Cereda, Godefridus J Peters, Maurizio Cantore. (2011) Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics1-12
CrossRef49
Zhen Fan, Richard Schraeder. (2011) The Changing Pathology of Lung Cancer. Surgical Oncology Clinics of North America 20:4, 637-653
CrossRef50
Tatsuya Yoshimasu, Shoji Oura, Fuminori Ohta, Yoshimitsu Hirai, Koma Naito, Rie Nakamura, Haruka Nishiguchi, Sayoko Hashimoto, Mitsumasa Kawago, Yoshitaka Okamura. (2011) Epidermal Growth Factor Receptor Mutations Are Associated with Docetaxel Sensitivity in Lung Cancer. Journal of Thoracic Oncology 6:10, 1658-1662
CrossRef51
Mladen V Tzvetkov, Gerrit Behrens, Valerie P O’Brien, Karin Hohloch, Jürgen Brockmöller, Peter Benöhr. (2011) Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 12:10, 1417-1427
CrossRef52
Brian M. Alexander, Xiao Zhe Wang, Andrzej Niemierko, David T. Weaver, Raymond H. Mak, Kevin S. Roof, Panagiotis Fidias, John Wain, Noah C. Choi. (2011) DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics
CrossRef53
Ardian Latifi, Khalid Abubaker, Natalie Castrechini, Alister C. Ward, Clifford Liongue, Francoise Dobill, Janani Kumar, Erik W. Thompson, Michael A. Quinn, Jock K. Findlay, Nuzhat Ahmed. (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. Journal of Cellular Biochemistry 112:10, 2850-2864
CrossRef54
Melissa H. Coleman, Raphael Bueno. (2011) Role of Adjuvant Chemotherapy in NSCLC (Stages I to III). Surgical Oncology Clinics of North America 20:4, 757-767
CrossRef55
Tõnu Vooder, Andres Metspalu. (2011) Investigating gene expression profile of non-small cell lung cancer. Central European Journal of Medicine 6:5, 608-615
CrossRef56
I. G. Hwang, J. S. Jang, J. H. Do, J. H. Kang, G. W. Lee, S. Y. Oh, H. C. Kwon, H. J. Jun, H. Y. Lim, S. Lee, K. C. Chi, S. J. Lee. (2011) Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Cancer Chemotherapy and Pharmacology 68:4, 935-944
CrossRef57
Zarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, Cecilia Bech, Claus Bøgelund Andersen, Eric Santoni-Rugiu. (2011) Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival. Journal of Thoracic Oncology1
CrossRef58
A. Vilmar, J. Garcia-Foncillas, M. Huarriz, E. Santoni-Rugiu, J.B. Sorensen. (2011) RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer
CrossRef59
J. Yin, C. Lu, J. Gu, S. M. Lippman, M. A. T. Hildebrandt, J. Lin, D. Stewart, M. R. Spitz, X. Wu. (2011) Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis
CrossRef60
Marieke A. Vollebergh, Jos Jonkers, Sabine C. Linn. (2011) Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cellular and Molecular Life Sciences
CrossRef61
L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins, O Kepp, M Castedo, G Kroemer. (2011) Molecular mechanisms of cisplatin resistance. Oncogene
CrossRef62
Rohit Lal, Deborah Enting, Hartmut Kristeleit. (2011) Systemic treatment of non-small-cell lung cancer. European Journal of Cancer 47, S375-S377
CrossRef63
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef64
Keith M Kerr. (2011) Personalized medicine for lung cancer: new challenges for pathology. Histopathologyno-no
CrossRef65
Kyoung-Won Seo, Hee-Woo Lee, Ye-In Oh, Jin-Ok Ahn, Ye-Rin Koh, Seung-Hyun Oh, Sung-Keun Kang, Hwa-Young Youn. (2011) Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. Cytotherapy 13:8, 944-955
CrossRef66
Thierry Le Chevalier. (2011) Management of early-stage non-small-cell lung cancer (NSCLC). European Journal of Cancer 47, S292-S293
CrossRef67
Chuan-Yong Mu, Jian-An Huang, Ying Chen, Cheng Chen, Xue-Guang Zhang. (2011) High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Medical Oncology 28:3, 682-688
CrossRef68
Zhe Long Liang, Eun-Kee Song, Young Bok Ko, Na-Ri Lee, Ho-Young Yhim, Heung-Tae Noh, Hwan Jung Yun, Kwang Sun Suh, Deog Yeon Jo, Samyong Kim, Jun-Sang Kim, Jin Man Kim, Hyo Jin Lee. (2011) Excision repair cross-complementation group 1 expression predicts response and survival in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy. Histopathology 59:3, 564-567
CrossRef69
A.-M. Ruppert, L. Belmont, A. Lavolé, V. Gounant, J. Assouad, J. Cadranel, M. Wislez. (2011) Les stratégies thérapeutiques péri-opératoires. Revue des Maladies Respiratoires Actualités 3:4, 346-352
CrossRef70
Manaljav Tseden-Ish, Yoo-Duk Choi, Hyun-Ju Cho, Hee-Jung Ban, In-Jae Oh, Kyu-Sik Kim, Sang-Yun Song, Kook-Joo Na, Sung-Ja Ahn, Song Choi, Young-Chul Kim. (2011) Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with ERCC1 expression and genotype. Respirologyno-no
CrossRef71
In-Jae Oh, Hee-Jung Ban, Kyu-Sik Kim, Sang-Yun Song, Kook-Joo Na, Yun-Hyeon Kim, Sung-Ja Ahn, Song Choi, Hyun-Ju Cho, Young-Chul Kim. (2011) Response to Gemcitabine-Platinum Chemotherapy by Single Nucleotide Polymorphisms of RRM1 and ERCC1 Genes in Patients with Non-Small Cell Lung Cancer. Thoracic Cancerno-no
CrossRef72
Qi Wang, Meizuo Zhong, Wei Liu, Jianhuang Li, Jin Huang, Le Zheng. (2011) Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP). Experimental Lung Research 37:7, 427-434
CrossRef73
Jules Lin, David G. Beer. (2011) Molecular Predictors of Prognosis in Lung Cancer. Annals of Surgical Oncology
CrossRef74
Yu-Jen Cheng, Jen-Wei Tsai, Kun-Chou Hsieh, Yu-Chi Yang, Yun-Ju Chen, Ming-Shyang Huang, Shyng-Shiou Yuan. (2011) Id1 promotes lung cancer cell proliferation and tumor growth through Akt-related pathway. Cancer Letters 307:2, 191-199
CrossRef75
Howard West. (2011) The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer. Current Oncology Reports 13:4, 280-289
CrossRef76
J. Köhler, M. Schuler. (2011) Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. Der Onkologe 17:8, 702-708
CrossRef77
Shirish M. Gadgeel. (2011) The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients. Current Oncology Reports 13:4, 272-279
CrossRef78
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl. (2011) A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1379-1391
CrossRef79
Thomas E. Stinchcombe, Jeffery Bogart, Nirmal K. Veeramachaneni, Robert Kratzke, Ramaswamy Govindan. (2011) Annual Review of Advances in Non-small Cell Lung Cancer Research. Journal of Thoracic Oncology 6:8, 1443-1450
CrossRef80
W.E.E. Eberhardt, T.C. Gauler, S. Welter, T. Krbek, M. Stuschke, C. Pöttgen. (2011) Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. Der Onkologe 17:8, 691-701
CrossRef81
Hai-bo Wei, Xiang-shi Lu, Li-hua Shang, Gang Xu, Jing Hu, De-hai Che, Fang Liu, Ying Wu, Guang-mei Zhang, Yan Yu. (2011) Meta-analysis of ERCC1 C118T/C8092A and MDR1 C3435T Polymorphism Predicts Outcome of Platinum-based Chemotherapies in Advanced Non-small Cell Lung Cancer. Archives of Medical Research
CrossRef82
Peter Schirmacher, Pierre Bedossa, Tania Roskams, Dina G. Tiniakos, Elizabeth M. Brunt, Jessica Zucman-Rossi, Michael P. Manns, Peter R. Galle. (2011) Fighting the bushfire in HCC trials. Journal of Hepatology 55:2, 276-277
CrossRef83
Hans Bösmüller, Sophie Haitchi-Petnehazy, Gerald Webersinke, Renate Marschon, Franz Roithmeier, Wolfgang Stummvoll, Tanja Fehm, Margit Klier-Richter, Irina Bonzheim, Annette Staebler, Falko Fend. (2011) Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Archiv 459:2, 183-191
CrossRef84
Ian Paul, Kienan I Savage, Jaine K Blayney, Elisabeth Lamers, Kathy Gately, Keith Kerr, Michael Sheaff, Kenneth Arthur, Derek J Richard, Peter W Hamilton, Jacqueline A James, Kenneth J O'Byrne, D Paul Harkin, Jennifer E Quinn, Dean A Fennell. (2011) PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. The Journal of Pathology 224:4, 564-574
CrossRef85
Yao-Chung Wu, Po-Hui Wang, Amy Tsai, Shun-Fa Yang, Shiuan-Chih Chen. (2011) Semi-quantitative expression of tissue inhibitor of matrix metalloproteinase-2 in cancer of uterine cervix. Journal of Surgical Oncology 104:2, 210-215
CrossRef86
Ingrid Vandenput, An Capoen, Lieve Coenegrachts, Godelieve Verbist, Philippe Moerman, Ignace Vergote, Frédéric Amant. (2011) Expression of ERCC1, p53, and Class III β-Tubulin Do Not Reveal Chemoresistance in Endometrial Cancer. International Journal of Gynecological Cancer 21:6, 1071-1077
CrossRef87
Dairong Li, Qi Zhou, Yu Liu, Yanqing Yang, Qiying Li. (2011) DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Medical Oncology
CrossRef88
Ji-Youn Han, Kyong-Ah Yoon, Jae Hee Park, Young Joo Lee, Geon Kook Lee, Jong Hee Han, Sung Jin Yoon, Tak Yun, Heung Tae Kim, Jin Soo Lee. (2011) DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer 117:14, 3201-3208
CrossRef89
B. Schultheis, G. Kummer, M. Zeth, E. Brendel, C. Xia, M. Kornacker, D. Strumberg. (2011) Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology
CrossRef90
Jong-Mu Sun, Myung-Ju Ahn, Min Jae Park, Hui-Young Lee, Jin Seok Ahn, Seungkoo Lee, Gu Kang, Joungho Han, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Keunchil Park. (2011) Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 80:3, 655-660
CrossRef91
Shannon Otsuka, Alexander C. Klimowicz, Karen Kopciuk, Stephanie K. Petrillo, Mie Konno, Desiree Hao, Huong Muzik, Erin Stolte, William Boland, Don Morris, Anthony M. Magliocco, D. Gwyn Bebb. (2011) CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:7, 1169-1178
CrossRef92
Nagahide Matsumura, Yasushi Nakamura, Yasuo Kohjimoto, Takeshi Inagaki, Yoshihito Nanpo, Hironao Yasuoka, Yasuo Ohashi, Isao Hara. (2011) The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU International 108:2b, E110-E116
CrossRef93
George Somlo, Sean K. Lau, Paul Frankel, H. Ben Hsieh, Xiaohe Liu, Lixin Yang, Robert Krivacic, Richard H. Bruce. (2011) Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Research and Treatment 128:1, 155-163
CrossRef94
Masayuki Takeda, Isamu Okamoto, Naoko Hirabayashi, Mami Kitano, Kazuhiko Nakagawa. (2011) Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 73:1, 103-109
CrossRef95
Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menis, Silvia Novello, Emilio Bria. (2011) Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer 73:1, 78-88
CrossRef96
Jennifer N. Earley, John J. Turchi. (2011) Interrogation of Nucleotide Excision Repair Capacity: Impact on Platinum-Based Cancer Therapy. Antioxidants & Redox Signaling 14:12, 2465-2477
CrossRef97
Alfredo Tartarone, Rose Lerose, Giuseppina Gallucci, Raffaele Ardito, Michele Aieta. (2011) Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical Oncology
CrossRef98
Lea Knez, Eva Sodja, Izidor Kern, Mitja Košnik, Tanja Cufer. (2011) Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review. Lung Cancer 72:3, 271-279
CrossRef99
B. Besse, G. Zalcman. (2011) Quelle séquence de traitement chez les patients EGFR mutés ?. Revue de Pneumologie Clinique 67, S24-S29
CrossRef100
Pedro Mendez, Miquel Taron, Teresa Moran, Marco A. Fernandez, Gerard Requena, Rafael Rosell. (2011) A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes. DNA Repair 10:6, 603-610
CrossRef101
Ruiz-Soto Rodrigo, Auger Nathalie, Tournay Elodie, Gomez-Abuin Gonzalo, Terrier Philippe, Drusch Françoise, Domont Julien, Cioffi Angela, Boulet Bérénice, Blay Jean-Yves, Coindre Jean-Michel, Bénard Jean, Bonvalot Sylvie, Le Cesne Axel. (2011) Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas. European Journal of Cancer 47:9, 1319-1327
CrossRef102
Ibrahim Aldoss, Syma Iqbal. (2011) Adjuvant Treatment and Predictors of Response in Colon Cancer. Seminars in Colon and Rectal Surgery 22:2, 131-136
CrossRef103
Geoff CHONG, Niall C TEBBUTT. (2011) Perioperative therapy for resectable gastric cancer: What does the future hold?. Asia-Pacific Journal of Clinical Oncology 7:2, 93-95
CrossRef104
Nagahiro Saijo. (2011) Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treatment Reviews
CrossRef105
Emre Tepeli, Vildan Caner, Nur Büyükpınarbaşılı, G. Ozan Çetin, Füsun Düzcan, Levent Elmas, Gülseren Bağcı. (2011) Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Molecular Biology Reports
CrossRef106
Shirish M. Gadgeel, John C. Ruckdeschel, Bhaumik B. Patel, Antoinette Wozniak, Andre Konski, Manuel Valdivieso, Deborah Hackstock, Wei Chen, Kimberly Belzer, Angelika M. Burger, Lauren Marquette, Andrew Turrisi. (2011) Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:5, 927-933
CrossRef107
Christine Vestergaard Madsen, Karina Dahl Steffensen, Marianne Waldstrøm, Anders Jakobsen. (2011) The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. Clinical Ovarian Cancer
CrossRef108
M. Ganzinelli, P. Mariani, D. Cattaneo, R. Fossati, R. Fruscio, S. Corso, F. Ricci, M. Broggini, G. Damia. (2011) Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations. European Journal of Cancer 47:7, 1086-1094
CrossRef109
Joanne Rossman, Vishnu Reddy, Alan Cantor, Debi Miley, Francisco Robert. (2011) Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer. Lung Cancer 72:2, 219-223
CrossRef110
Marc Campayo, Nuria Viñolas, Alfons Navarro, Enric Carcereny, Francesc Casas, Bernat Gel, Tania Diaz, Josep Maria Gimferrer, Ramon M. Marrades, Jose Ramirez, Mariano Monzo. (2011) Single Nucleotide Polymorphisms in Tobacco Metabolism and DNA Repair Genes and Prognosis in Resected Non-Small-Cell Lung Cancer. Journal of Surgical Research 167:1, e5-e12
CrossRef111
Martin J. Edelman, Marianna Shvartsbeyn. (2011) Epothilones in Development for Non–Small-Cell Lung Cancer: Novel Anti-Tubulin Agents With the Potential to Overcome Taxane Resistance. Clinical Lung Cancer
CrossRef112
Jean-Damien Charrier, Steven J. Durrant, Julian M. C. Golec, David P. Kay, Ronald M. A. Knegtel, Somhairle MacCormick, Michael Mortimore, Michael E. O'Donnell, Joanne L. Pinder, Philip M. Reaper, Alistair P. Rutherford, Paul S. H. Wang, Stephen C. Young, John R. Pollard. (2011) Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents. Journal of Medicinal Chemistry 54:7, 2320-2330
CrossRef113
Philip M Reaper, Matthew R Griffiths, Joanna M Long, Jean-Damien Charrier, Somhairle MacCormick, Peter A Charlton, Julian M C Golec, John R Pollard. (2011) Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature Chemical Biology 7:7, 428-430
CrossRef114
T. Reiman, R. Lai, A. S. Veillard, E. Paris, J. C. Soria, R. Rosell, M. Taron, S. Graziano, R. Kratzke, L. Seymour, F. A. Shepherd, J. P. Pignon, P. Seve, . (2011) Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Annals of Oncology
CrossRef115
Yan Shi, Li Chen, Jie Li, Ya-Li Lv, Qiong Sun, Ling-Xiong Wang, Shun-Chang Jiao. (2011) Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumor Biology 32:2, 381-390
CrossRef116
Thomas Stricker, Daniel V.T. Catenacci, Tanguy Y. Seiwert. (2011) Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology 38:2, 173-185
CrossRef117
Shigeru Ueda, Ken Shirabe, Kazutoyo Morita, Kenji Umeda, Hiroto Kayashima, Hideaki Uchiyama, Yuji Soejima, Akinobu Taketomi, Yoshihiko Maehara. (2011) Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma. Annals of Surgical Oncology 18:4, 1204-1211
CrossRef118
M. Dediu. (2011) Adjuvant chemotherapy in stage IB NSCLC: implication of the new TNM staging system. memo - Magazine of European Medical Oncology 4:1, 16-18
CrossRef119
Kayo Osawa. (2011) SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients. Pharmacogenomics 12:4, 445-447
CrossRef120
S R Park, S-Y Kong, B-H Nam, I J Choi, C G Kim, J Y Lee, S J Cho, Y W Kim, K W Ryu, J H Lee, J Rhee, Y-I Park, N K Kim. (2011) CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. British Journal of Cancer 104:7, 1126-1134
CrossRef121
Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri. (2011) Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians 61:2, 91-112
CrossRef122
Rui Gao, Kelie Reece, Tristan Sissung, Eddie Reed, Douglas K. Price, William D. Figg. (2011) The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 708:1-2, 21-27
CrossRef123
Sacha I Rothschild, Oliver Gautschi, Primo N Lara, Philip C Mack, David R Gandara. (2011) Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Current Opinion in Oncology 23:2, 150-157
CrossRef124
Kyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, Satoru Miura, Rieko Kaira, Masato Abe, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Tateaki Naito, Haruyasu Murakami, Toshiaki Takahashi, Haruhiko Kondo, Takashi Nakajima, Masahiro Endo, Nobuyuki Yamamoto. (2011) Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and β III-Tubulin in Thymic Epithelial Tumors. Journal of Thoracic Oncology 6:3, 606-613
CrossRef125
B. Besse, C. Massard, V. Haddad, F. Andre, A. Dunant, R. Pirker, K. A. Olaussen, E. Brambilla, P. Fouret, J. C. Soria. (2011) ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of Oncology 22:3, 575-581
CrossRef126
David Quinn, Mitchell Gross. (2011) Show us a sign: the search for “game changing” prostate cancer biomarkers. The Lancet Oncology 12:3, 204-206
CrossRef127
Jenny Andrews, Paul Yeh, William Pao, Leora Horn. (2011) Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer. The Cancer Journal 17:2, 104-113
CrossRef128
Shu-zhen Wei, Ping Zhan, Mei-qi Shi, Yi Shi, Qian Qian, Li-ke Yu, Yong Song. (2011) Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Medical Oncology 28:1, 315-321
CrossRef129
Qiang Li, Chengxue Dang, Zhigang Liu, Ruifang Sun. (2011) ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy. The Chinese-German Journal of Clinical Oncology 10:2, 92-95
CrossRef130
Anthony W. Kim, Marta Batus, Ronald Myint, Mary J. Fidler, Sanjib Basu, Philip Bonomi, L. Penfield Faber, Sean C. Wightman, William H. Warren, Maria McIntire, Leonidas D. Arvanitis, Paolo Gattuso, Xiulong Xu, Michael J. Liptay. (2011) Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer 71:2, 186-190
CrossRef131
David J. Stewart, Carmen Behrens, Jack Roth, Ignacio I. Wistuba. (2011) Exponential decay nonlinear regression analysis of patient survival curves: Preliminary assessment in non-small cell lung cancer. Lung Cancer 71:2, 217-223
CrossRef132
William D. Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James Jett, Montserrat Sanchez-Cespedes, Jean-Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio Wistuba, Pan-Chyr Yang, Denise Aberle, Christian Brambilla, Douglas Flieder, Wilbur Franklin, Adi Gazdar, Michael Gould, Philip Hasleton, Douglas Henderson, Bruce Johnson, David Johnson, Keith Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming Tsao, David Yankelewitz. (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology 6:2, 244-285
CrossRef133
Ki Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sung Hyun Kim, Suee Lee, Kyung A Kwon, Jin Seok Jang, Min Chan Kim, Su-Jin Kim, Hyo-Jin Kim. (2011) Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16:1, 74-82
CrossRef134
Y.- W. Won, Y. H. Park, M. J. Ahn, I.- G. Do, Y. H. Ko, K. Park. (2011) A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology 22:2, 417-423
CrossRef135
Jong-Sup Park, Eun Kyung Jeon, Sang Hoon Chun, Hye Seong Won, Ahwon Lee, Soo Young Hur, Keun Ho Lee, Seog-Nyeon Bae, Sei-Chul Yoon, Sook Hee Hong. (2011) ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer. Gynecologic Oncology 120:2, 275-279
CrossRef136
Joshua A. Roth, Josh J. Carlson. (2011) Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer. Journal of Gastrointestinal Cancer
CrossRef137
Han Suk Ryu, Xianhua Xu, Hyojin Kim, Jong-Suk Lee, Sanghoon Jheon, Jin-Haeng Chung. (2011) ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC. The Korean Journal of Pathology 45:1, 45
CrossRef138
Carolin M. Grimminger, Peter V. Danenberg. (2011) Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. European Archives of Oto-Rhino-Laryngology 268:1, 5-16
CrossRef139
Yoichi Nakamura, Hiroshi Soda, Mikio Oka, Akitoshi Kinoshita, Minoru Fukuda, Masaaki Fukuda, Hiroshi Takatani, Seiji Nagashima, Yoshifumi Soejima, Takashi Kasai, Katsumi Nakatomi, Noriyuki Masuda, Kazuhiro Tsukamoto, Shigeru Kohno. (2011) Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 121-127
CrossRef140
Rafael Rosell, Miquel Taron, Bartomeu Massuti, Nuria Mederos, Ignacio Magri, Mariacarmela Santarpia, Jose Miguel Sanchez. (2011) Predicting Response to Chemotherapy With Early-Stage Lung Cancer. The Cancer Journal 17:1, 49-56
CrossRef141
Samuel P. Hammar, Sanja Dacic. 2011. Immunohistology of Lung and Pleural Neoplasms. , 369-463.
CrossRef142
Alex Soltermann, Sandra Kilgus-Hawelski, Silvia Behnke, Martina Storz, Holger Moch, Beata Bode. (2011) Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. Journal of Clinical Bioinformatics 1:1, 25
CrossRef143
Janna Sand-Dejmek, Guillaume Adelmant, Bijan Sobhian, Anne S Calkins, Jarrod Marto, Dirk J Iglehart, Jean-Bernard Lazaro. (2011) Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin. Molecular Cancer 10:1, 74
CrossRef144
Mark D. Vincent. 2011. Cancer: Beyond Speciation. , 283-350.
CrossRef145
Desirée Hao, Harold Y. Lau, Misha Eliasziw, Alan Box, Román Diaz, Alexander C. Klimowicz, Brian Shin, Susan P. Lees-Miller, Anthony M. Magliocco. (2011) Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head & Neckn/a-n/a
CrossRef146
George R. Simon, Michael J. Schell, Mubeena Begum, Jongphil Kim, Alberto Chiappori, Eric Haura, Scott Antonia, Gerold Bepler. (2011) Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancern/a-n/a
CrossRef147
Dong M. Shin, Fadlo R. Khuri. (2011) Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neckn/a-n/a
CrossRef148
Ekrem Cengiz Seyhan, Sedat Altin, Erdogan Cetinkaya, Sinem Sokucu, Hulya Abali, Nur Buyukpinarbasili, Neslihan Fener. (2011) Prognostic Significance of ERCC1 Expression in Resected Non Small Cell Lung Carcinoma. Annals of Thoracic and Cardiovascular Surgery 17:2, 110-117
CrossRef149
Alex Chang. (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71:1, 3-10
CrossRef150
Qi-En Wang, Keisha Milum, Chunhua Han, Yi-Wen Huang, Gulzar Wani, Jürgen Thomale, Altaf A Wani. (2011) Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Molecular Cancer 10:1, 24
CrossRef151
Gerold Bepler, Ken André Olaussen, Anne-Lise Vataire, Jean-Charles Soria, Zhong Zheng, Ariane Dunant, Jean-Pierre Pignon, Michael J. Schell, Pierre Fouret, Robert Pirker, Martin Filipits, Elisabeth Brambilla. (2011) ERCC1 and RRM1 in the International Adjuvant Lung Trial by Automated Quantitative in Situ Analysis. The American Journal of Pathology 178:1, 69-78
CrossRef152
Tai-Jan Chiu, Chang-Han Chen, Chih-Yen Chien, Shau-Hsuan Li, Hsin-Ting Tsai, Yi-Ju Chen. (2011) High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. Journal of Translational Medicine 9:1, 31
CrossRef153
Gérard Zalcman, Emmanuel Bergot, Christian Creveuil, Guénaëlle Levallet, Emmanuèle Lechapt. (2011) Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. Current Opinion in Oncology 23:1, 106-111
CrossRef154
Katey S. S. Enfield, Greg L. Stewart, Larissa A. Pikor, Carlos E. Alvarez, Stephen Lam, Wan L. Lam, Raj Chari. (2011) MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer. Journal of Biomedicine and Biotechnology 2011, 1-15
CrossRef155
Seong Hyun Jeong, Jae Ho Han, Jang Hee Kim, Mi Sun Ahn, Yoon Ho Hwang, Hyun Woo Lee, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Kwang Jae Lee, Seung Soo Sheen, Ho-Yeong Lim. (2011) Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy. Digestive Diseases and Sciences 56:1, 131-138
CrossRef156
Ramya Varadarajan, Andrea S. Licht, Andrew J. Hyland, Laurie A. Ford, Sheila N.J. Sait, Annemarie W. Block, Maurice Barcos, Maria R. Baer, Eunice S. Wang, Meir Wetzler. (2011) Smoking adversely affects survival in acute myeloid leukemia patients. International Journal of Cancern/a-n/a
CrossRef157
Bryan Corrin, Andrew G. Nicholson. 2011. Tumours. , 531-705.
CrossRef158
Beate Köberle, Maja T. Tomicic, Svetlana Usanova, Bernd Kaina. (2010) Cisplatin resistance: Preclinical findings and clinical implications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1806:2, 172-182
CrossRef159
Shirish M. Gadgeel, Michele L. Cote, Ann G. Schwartz, Larry H. Matherly, Antoinette Wozniak, Gerold Bepler. (2010) Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resistance Updates 13:6, 196-204
CrossRef160
Arjun V. Balar, Matthew I. Milowsky. (2010) DO MIXED HISTOLOGIC FEATURES AFFECT SURVIVAL BENEFIT FROM NEO-ADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER?. BJU Internationalno-no
CrossRef161
David S. Yoo, Terence Z. Wong, David M. Brizel. (2010) The Role of Adaptive and Functional Imaging Modalities in Radiation Therapy: Approach and Application from a Radiation Oncology Perspective. Seminars in Ultrasound, CT, and MRI 31:6, 444-461
CrossRef162
Athanasios G. Pallis, Michalis V. Karamouzis. (2010) DNA repair pathways and their implication in cancer treatment. Cancer and Metastasis Reviews 29:4, 677-685
CrossRef163
Edward B. Garon, Steven M. Dubinett. (2010) Poly(ADP-Ribose) Polymerase Inhibitors. Journal of Thoracic Oncology 5, S455-S456
CrossRef164
KYOUNG Ha KIM, IN-GU DO, HYEONG SU KIM, MYUNG HEE CHANG, HYO SONG KIM, HYUN JUNG JUN, JIEUN UHM, SEONG YOON YI, DO HYOUNG LIM, SANG HOON JI, MIN JAE PARK, JEEYUN LEE, SE HOON PARK, GHEE YOUNG KWON, HO YEONG LIM. (2010) Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 118:12, 941-948
CrossRef165
A. Soltermann, I. Opitz, V. Tischler, S. Thies, L. Morra, R. A. Stahel, W. Weder, H. Moch. (2010) EMT in NSCLC and malignant pleural mesothelioma. memo - Magazine of European Medical Oncology 3:4, 180-184
CrossRef166
David R. Gandara, Peter Grimminger, Philip C. Mack, Primo N. Lara, Tianhong Li, Peter V. Danenberg, Kathleen D. Danenberg. (2010) Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1933-1938
CrossRef167
Susana Cedrés Pérez, Isela Quispe, Pablo Martínez, Marina Longo, Eva Rodríguez, César Serrano, Eva Muñoz, Esther Pallisa, Enriqueta Felip. (2010) Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology 12:12, 829-835
CrossRef168
Jae Jin Lee, Chi Hoon Maeng, Seon Kyung Baek, Gou Young Kim, Jee-Hong Yoo, Cheon Woong Choi, Yee Hyung Kim, Young-Tae Kwak, Dae-Hyun Kim, Young Kyung Lee, Jung Bo Kim, Si-Young Kim. (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70:2, 205-210
CrossRef169
Corinne M. Doll, Michael Prystajecky, Misha Eliasziw, Alexander C. Klimowicz, Stephanie K. Petrillo, Peter S. Craighead, Desiree Hao, Roman Diaz, Susan P. Lees-Miller, Anthony M. Magliocco. (2010) Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiotherapy and Oncology 97:2, 352-359
CrossRef170
Stefanie Scheil-Bertram, Patricia Tylus-Schaaf, Andreas du Bois, Philipp Harter, Matthias Oppitz, Nina Ewald-Riegler, Annette Fisseler-Eckhoff. (2010) Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecologic Oncology 119:2, 325-331
CrossRef171
Shengxiang Ren, Songwen Zhou, Ling Zhang, Jianfang Xu, Meijun Lv, Jie Zhang, Caicun Zhou, Jie Zhang. (2010) High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients. Cancer Investigation 28:10, 1078-1083
CrossRef172
Z. Sun, J. Chen, J. Aakre, R. S. Marks, Y. Y. Garces, R. Jiang, O. Idowu, J. M. Cunningham, Y. Liu, V. S. Pankratz, P. Yang. (2010) Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Annals of Oncology 21:10, 2011-2016
CrossRef173
Sandra Geiger, Marcus Schlemmer, Volker Heinemann, Hans Joachim Stemmler. (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. Anti-Cancer Drugs 21:9, 799-804
CrossRef174
Shu-Xia Li, Ashley Sjolund, Lyndsay Harris, Joann B. Sweasy. (2010) DNA repair and personalized breast cancer therapy. Environmental and Molecular Mutagenesis 51:8-9, 897-908
CrossRef175
K. Konopa. (2010) Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer?. Annals of Oncology 21:Supplement 7, vii199-vii202
CrossRef176
T. Le Chevalier. (2010) Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?. Annals of Oncology 21:Supplement 7, vii196-vii198
CrossRef177
Julien Cazejust, Thierry De Baère, Anne Auperin, Frédéric Deschamps, Lukas Hechelhammer, Mohamed Abdel-Rehim, Martin Schlumberger, Sophie Leboulleux, Eric Baudin. (2010) Transcatheter Arterial Chemoembolization for Liver Metastases in Patients with Adrenocortical Carcinoma. Journal of Vascular and Interventional Radiology 21:10, 1527-1532
CrossRef178
S Lee, Y H Park, K H Kim, E Y Cho, Y C Ahn, K Kim, Y-M Shim, J S Ahn, K Park, Y-H Im. (2010) Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. British Journal of Cancer 103:6, 845-851
CrossRef179
A. C. Vilmar, E. Santoni-Rugiu, J. B. Sorensen. (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Annals of Oncology 21:9, 1817-1824
CrossRef180
N. Saijo. (2010) Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy. Japanese Journal of Clinical Oncology 40:9, 855-862
CrossRef181
N. Saijo, M. Fukuoka, S. Thongprasert, Y. Ichinose, T. Mitsudomi, T. S. K. Mok, Y. Ohe, K. Park, Y.-L. Wu. (2010) Lung Cancer Working Group Report. Japanese Journal of Clinical Oncology 40:Supplement 1, i7-i12
CrossRef182
Andre T. Brunetto, Craig P. Carden, James Myerson, Ana Luisa Faria, Sue Ashley, Sanjay Popat, Mary E. R. OʼBrien. (2010) Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. Journal of Thoracic Oncology 5:9, 1397-1403
CrossRef183
Haiying Cheng, Xunhai Xu, Daniel B. Costa, Charles A. Powell, Balazs Halmos. (2010) Molecular Testing in Lung Cancer: The Time Is Now. Current Oncology Reports 12:5, 335-348
CrossRef184
Céline J. Rocca, Virginie Poindessous, Daniele G. Soares, Karima El Ouadrani, Alain Sarasin, Eric Guérin, Aimery de Gramont, João A.P. Henriques, Alexandre E. Escargueil, Annette K. Larsen. (2010) The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: Implications for recognition and repair of antitumor alkylators. Biochemical Pharmacology 80:3, 335-343
CrossRef185
Sandra C Tomaszek, Marianne Huebner, Dennis A Wigle. (2010) Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. Expert Review of Respiratory Medicine 4:4, 499-508
CrossRef186
Giannis Mountzios, Meletios-Athanassios Dimopoulos, Jean-Charles Soria, Despina Sanoudou, Christos A. Papadimitriou. (2010) Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. Critical Reviews in Oncology/Hematology 75:2, 94-109
CrossRef187
Christophe M. Raynaud, Juana Hernandez, Frédérique P. Llorca, Paolo Nuciforo, Marie-Christine Mathieu, Frederic Commo, Suzette Delaloge, Laure Sabatier, Fabrice André, Jean-Charles Soria. (2010) DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. American Journal of Clinical Oncology 33:4, 341-345
CrossRef188
Albiruni R.A. Razak, Lillian L. Siu, Fei-Fei Liu, Emma Ito, Brian O’Sullivan, Kelvin Chan. (2010) Nasopharyngeal carcinoma: The next challenges. European Journal of Cancer 46:11, 1967-1978
CrossRef189
Jian Li, Zhen-Nan Li, Li-Chao Yu, Qian-Lei Bao, Jian-Rong Wu, Shun-Bing Shi, Xiao-Qin Li. (2010) Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69:1, 116-122
CrossRef190
Charles Ferté, Fabrice André, Jean-Charles Soria. (2010) Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nature Reviews Clinical Oncology 7:7, 367-380
CrossRef191
Fabien Maldonado, James R Jett. (2010) Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. Current Opinion in Pulmonary Medicine 16:4, 315-320
CrossRef192
In Sil Choi, Hye Seung Lee, Keun-Wook Lee, Haeryoung Kim, Ki Hwan Kim, Yu Jung Kim, Jee Hyun Kim, Woo Ho Kim, Jong Seok Lee. (2010) Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Medical Oncology
CrossRef193
F Toffalorio, E Giovannetti, T De Pas, D Radice, G Pelosi, M Manzotti, D Minocci, L Spaggiari, G Spitaleri, C Noberasco, C Catania, S Boselli, R Danesi, F de Braud. (2010) Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. The Pharmacogenomics Journal 10:3, 180-190
CrossRef194
P Ceppi, M Papotti, G Scagliotti. (2010) New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. Advances in Medical Sciences 55:1, 22-25
CrossRef195
Xin Wang, Jun Zhao, Lu Yang, Li Mao, Tongtong An, Hua Bai, Shuhang Wang, Xuyi Liu, Guoshuang Feng, Jie Wang. (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Medical Oncology 27:2, 484-490
CrossRef196
Stephen L. Graziano, Lin Gu, Xiaofei Wang, Arthur H. Tatum, Robin T. Vollmer, Gary M. Strauss, Robert Kratzke, Arkadiusz Z. Dudek, Everett E. Vokes, Mark R. Green. (2010) Prognostic Significance of Mucin and p53 Expression in Stage IB Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:6, 810-817
CrossRef197
Helen Gogas, Dimitrios Pectasides, Ioannis Kostopoulos, Evangelos Lianos, Dimosthenis Skarlos, George Papaxoinis, Mattheos Bobos, Haralabos P. Kalofonos, Kalliopi Petraki, Kitty Pavlakis, Dimitrios Bafaloukos, George Fountzilas. (2010) Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. Clinical Breast Cancer 10:3, 230-237
CrossRef198
Adam Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen. (2010) ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. European Journal of Cancer 46:9, 1554-1562
CrossRef199
Chang Hyun Kang, Bo Gun Jang, Dong-Wan Kim, Doo Hyun Chung, Young Tae Kim, Sanghoon Jheon, Sook-Whan Sung, Joo Hyun Kim. (2010) The prognostic significance of ERCC1, BRCA1, XRCC1, and βIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:3, 478-483
CrossRef200
G. Rocco, F. Perrone, A. Rossi, C. Gridelli. (2010) Surgical Management of Non-small Cell Lung Cancer with Mediastinal Lymphadenopathy. Clinical Oncology 22:5, 325-333
CrossRef201
K R Fareed, A Al-Attar, I N Soomro, P V Kaye, J Patel, D N Lobo, S L Parsons, S Madhusudan. (2010) Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. British Journal of Cancer 102:11, 1600-1607
CrossRef202
Chunxia Su, Songwen Zhou, Ling Zhang, Shengxiang Ren, Jianfang Xu, Jie Zhang, Meijun Lv, Jie Zhang, Caicun Zhou. (2010) ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Medical Oncology
CrossRef203
Navneet Singh, Amanjit Bal, Ashutosh N Aggarwal, Ashim Das, Digambar Behera. (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncology 6:5, 741-767
CrossRef204
Richard L. Schilsky. (2010) Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery 9:5, 363-366
CrossRef205
Mark A. Socinski. (2010) The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:3, 149-159
CrossRef206
Ana Bosch, Pilar Eroles, Rosa Zaragoza, Juan R. Viña, Ana Lluch. (2010) Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews 36:3, 206-215
CrossRef207
Aristotelis Bamias, M. Karina, P. Papakostas, I. Kostopoulos, M. Bobos, G. Vourli, E. Samantas, Ch. Christodoulou, G. Pentheroudakis, D. Pectasides, M. A. Dimopoulos, G. Fountzilas. (2010) A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology 65:6, 1009-1021
CrossRef208
Si Yeol Song, Seong-Yun Jeong, Heon Joo Park, Seung-Il Park, Dong Kwan Kim, Yong Hee Kim, Seong Soo Shin, Sang-wook Lee, Seung Do Ahn, Jong Hoon Kim, Jung Shin Lee, Eun Kyung Choi. (2010) Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer. Lung Cancer 68:2, 278-282
CrossRef209
Shan Luo, Ping Chen, Zi-chao Luo, Ping Zhang, Ping Sun, Wei Shi, Zhi-yong Li, Xiao-long Zhang, Li-qiang Wang, Xin Chen, Yu-quan Wei, Yan-jun Wen. (2010) Combination of vesicular stomatitis virus matrix protein gene therapy with low-dose cisplatin improves therapeutic efficacy against murine melonoma. Cancer Science 101:5, 1219-1225
CrossRef210
H. Cheng, N. Sun, X. Sun, B. Chen, F. Li, J. Feng, L. Cheng, Y. Cao. (2010) Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochimica et Biophysica Sinica 42:5, 311-317
CrossRef211
Seong Hyun Jeong, Jae Ho Jung, Jae Ho Han, Jang Hee Kim, Yong-Won Choi, Hyun Woo Lee, Seok Yun Kang, Yoon Ho Hwang, Mi Sun Ahn, Jin-Hyuk Choi, Young Taek Oh, Mison Chun, Seunghee Kang, Kwang Joo Park, Sung Chul Hwang, Seung Soo Sheen. (2010) Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 68:2, 288-294
CrossRef212
Y. Y. Shao, K. T. Kuo, F. C. Hu, Y. S. Lu, C. S. Huang, J. Y. Liau, W. C. Lee, C. Hsu, W. H. Kuo, K. J. Chang, C. H. Lin, A. L. Cheng. (2010) Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Japanese Journal of Clinical Oncology 40:4, 286-293
CrossRef213
Birgit Guldhammer Skov, Bente Holm, Anders Erreboe, Torsten Skov, Anders Mellemgaard. (2010) ERCC1 and Ki67 in Small Cell Lung Carcinoma and Other Neuroendocrine Tumors of the Lung. Journal of Thoracic Oncology 5:4, 453-459
CrossRef214
Alberto A. Chiappori, Zhong Zheng, Tingan Chen, Bhupendra Rawal, Michael J. Schell, Brian P. Mullaney, Gerold Bepler. (2010) Features of Potentially Predictive Biomarkers of Chemotherapeutic Efficacy in Small Cell Lung Cancer. Journal of Thoracic Oncology 5:4, 484-490
CrossRef215
Nabil Saba, John Kauh, Dong M. Shin. 2010. Designing and Conducting Phase III Studies. .
CrossRef216
Sharad Goyal, Rahul R. Parikh, Camille Green, Devora Schiff, Meena S. Moran, Qifeng Yang, Bruce G. Haffty. (2010) Clinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 76:3, 679-684
CrossRef217
Luca Toschi, Federico Cappuzzo. (2010) Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology 5:1, 5-17
CrossRef218
Hyun Woo Lee, Yoon Ho Hwang, Jae Ho Han, Jin-Hyuk Choi, Seok Yun Kang, Seong Hyun Jeong, Mi Sun Ann, Young Taek Oh, Jang Hee Kim, Chul Ho Kim, Seung Soo Sheen. (2010) High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncology 46:3, 209-213
CrossRef219
Youngil Koh, Bogun Jang, Sae-Won Han, Tae-Min Kim, Do-Youn Oh, Se-Hoon Lee, Chang Hyun Kang, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Young Tae Kim, Tae-You Kim, Young-Whan Kim, Joo Hyun Kim, Dae Seog Heo, Yung-Jue Bang. (2010) Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:3, 320-325
CrossRef220
David E. Gerber, Hak Choy. (2010) Cetuximab in combination therapy: from bench to clinic. Cancer and Metastasis Reviews 29:1, 171-180
CrossRef221
Tony Dhillon, Francesco A. Mauri, Guido Bellezza, Lucio Cagini, Mattia Barbareschi, Bernard V. North, Michael J. Seckl. (2010) Overexpression of the Mammalian Target of Rapamycin. Journal of Thoracic Oncology 5:3, 314-319
CrossRef222
S. Chijiwa, C. Masutani, F. Hanaoka, S. Iwai, I. Kuraoka. (2010) Polymerization by DNA polymerase is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells. Carcinogenesis 31:3, 388-393
CrossRef223
Songjian Chen, Xia Huo, Yi Lin, Hao Ban, Yincheng Lin, Weiqiu Li, Bao Zhang, William W. Au, Xijin Xu. (2010) Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. International Journal of Hygiene and Environmental Health 213:2, 140-145
CrossRef224
María Martín Ureste, Regina Gironés Sarrió, Joaquín Montalar Salcedo. (2010) Biomarkers in bronchopulmonary cancer. Clinical and Translational Oncology 12:2, 92-99
CrossRef225
Pascal Sève, Tony Reiman, Charles Dumontet. (2010) The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:2, 136-143
CrossRef226
Laura R. Triano, Hari Deshpande, Scott N. Gettinger. (2010) Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 70:2, 167-179
CrossRef227
Qing-Fang Li, Ru-Yong Yao, Ke-wei Liu, Hong-Ying Lv, Tao Jiang, Jun Liang. (2010) Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer. Journal of Korean Medical Science 25:6, 846
CrossRef228
Luis E. Raez, Svetlana Kobina, Edgardo S. Santos. (2010) Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:1, 18-24
CrossRef229
Tomoyoshi Takenaka, Tokujiro Yano, Chikako Kiyohara, Naoko Miura, Hidenori Kouso, Taro Ohba, Takuro Kometani, Fumihiro Shoji, Ichiro Yoshino, Yoshihiko Maehara. (2010) Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67:1, 101-107
CrossRef230
Stephen G. SPIRO, Nichole T. TANNER, Gerard A. SILVESTRI, Sam M. JANES, Eric LIM, Johan F. VANSTEENKISTE, Robert PIRKER. (2010) Lung cancer: Progress in diagnosis, staging and therapy. Respirology 15:1, 44-50
CrossRef231
Ewa Szutowicz, Rafał Dziadziuszko. (2010) Quantitative immunohistochemistry in lung cancer: clinical perspective. Folia Histochemica et Cytobiologica 48:1, 7-11
CrossRef232
Ronald Natale. 2010. Adjuvant and Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. , 247-251.
CrossRef233
Toshihiro MUTO, Masahiko KOIKE, Yuichi ITO, Goro NAKAYAMA, Michitaka FUJIWARA, Yasuhiro KODERA, Akimasa NAKAO. (2010) ANALYSIS OF THE ADVERSE EVENTS OF STANDARD NEOADJUVANT CHEMOTHERAPY USED FOR ESOPHAGEAL CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 71:2, 335-343
CrossRef234
Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang. (2010) Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy. Cancer Research and Treatment 42:2, 101
CrossRef235
Danielle Shafer, Kathy Albain. (2009) Lung Cancer Outcomes in Women. Seminars in Oncology 36:6, 532-541
CrossRef236
David Planchard, Yohann Loriot, Aicha Goubar, Fréderic Commo, Jean-Charles Soria. (2009) Differential Expression of Biomarkers in Men and Women. Seminars in Oncology 36:6, 553-565
CrossRef237
Satoshi Ikeda, Kazuhiko Takabe, Keiko Suzuki. (2009) Expression of ERCC1 and class IIIβ tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathology International 59:12, 863-867
CrossRef238
Chang Hyun Kang, Bo Gun Jang, Dong-Wan Kim, Doo Hyun Chung, Young Tae Kim, Sanghoon Jheon, Sook-Whan Sung, Joo Hyun Kim. (2009) Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival. Journal of Thoracic Oncology 4:11, 1307-1312
CrossRef239
Carole Massabeau, Isabelle Rouquette, Valérie Lauwers-Cances, Julien Mazières, Jean-Marc Bachaud, Jean-Pierre Armand, Marie-Bernadette Delisle, Gilles Favre, Christine Toulas, Elizabeth Cohen-Jonathan-Moyal. (2009) Basic Fibroblast Growth Factor-2/β3 Integrin Expression Profile: Signature of Local Progression After Chemoradiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 75:3, 696-702
CrossRef240
Jian Li, Zhen-Nan Li, Yong-Jie Du, Xiao-Qin Li, Qian-Lei Bao, Ping Chen. (2009) Expression of <i>MRP1, BCRP, LRP,</i> and <i>ERCC1</i> in Advanced Non–Small-Cell Lung Cancer: Correlation With Response to Chemotherapy and Survival. Clinical Lung Cancer 10:6, 414-421
CrossRef241
David R. Gandara, Philip C. Mack, Tianhong Li, Primo N. Lara ., Roy S. Herbst. (2009) Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012. Clinical Lung Cancer 10:6, 392-394
CrossRef242
Lina Carvalho. (2009) Reclassificação do carcinoma broncopulmonar: Diferenciação do tipo histológico em biópsias por imuno-histoquímica. Revista Portuguesa de Pneumologia (English Edition) 15:6, 1101-1119
CrossRef243
Linda E Coate, Thomas John, Ming-Sound Tsao, Frances A Shepherd. (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. The Lancet Oncology 10:10, 1001-1010
CrossRef244
Michaela J Higgins, David S Ettinger. (2009) Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy 9:10, 1365-1378
CrossRef245
Carlos Gomez-Roca, Christophe M. Raynaud, Frederique Penault-Llorca, Olaf Mercier, Frederic Commo, Luc Morat, Laure Sabatier, Philipe Dartevelle, Estelle Taranchon, Benjamin Besse, Pierre Validire, Antoine Italiano, Jean-Charles Soria. (2009) Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. Journal of Thoracic Oncology 4:10, 1212-1220
CrossRef246
Lucyna Kepka, Arkadiusz Sprawka, Francesc Casas, Sherif Abdel-Wahab, Jai Prakash Agarwal, Branislav Jeremic. (2009) Combination of radiotherapy and chemotherapy in locally advanced NSCLC. Expert Review of Anticancer Therapy 9:10, 1389-1403
CrossRef247
Boone Goodgame, Thomas E. Stinchcombe, George Simon, Antoinette Wozniak, Ramaswamy Govindan. (2009) Recent Advances in Lung Cancer. Journal of Thoracic Oncology 4:10, 1293-1300
CrossRef248
Thomas A. d’Amato, Brian L. Pettiford, Mathew J. Schuchert, Ricardo Parker, William A. Ricketts, James D. Luketich, Rodney J. Landreneau. (2009) Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy. Annals of Surgical Oncology 16:10, 2848-2855
CrossRef249
Howard West, Rogerio Lilenbaum, David Harpole, Antoinette Wozniak, Lecia Sequist. (2009) Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:Supplement 2, S1029-S1039
CrossRef250
Hyun Woo Lee, Yong-Won Choi, Jae Ho Han, Jang Hee Kim, Jae Ho Jung, Seong Hyun Jeong, Seok Yun Kang, Jin-Hyuk Choi, Young Taek Oh, Kwang Joo Park, Sung Chul Hwang, Seung Soo Sheen. (2009) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 65:3, 377-382
CrossRef251
Andrea B Apolo, Matthew Milowsky, Dean F Bajorin. (2009) Clinical states model for biomarkers in bladder cancer. Future Oncology 5:7, 977-992
CrossRef252
Judit Pápay, Zoltán Sápi, Gábor Egri, Márton Gyulai, Béla Szende, György Losonczy, József Tímár, Judit Moldvay. (2009) Platinum-Based Chemotherapy in Lung Cancer Affects the Expression of Certain Biomarkers Including ERCC1. Pathology & Oncology Research 15:3, 445-450
CrossRef253
H Akita, Z Zheng, Y Takeda, C Kim, N Kittaka, S Kobayashi, S Marubashi, I Takemasa, H Nagano, K Dono, S Nakamori, M Monden, M Mori, Y Doki, G Bepler. (2009) Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28:32, 2903-2909
CrossRef254
Edgardo S Santos, Cesar A Perez, Luis E Raez. (2009) How is gene-expression profiling going to challenge the future management of lung cancer?. Future Oncology 5:6, 827-835
CrossRef255
Penelope A. Bradbury, Matthew H. Kulke, Rebecca S. Heist, Wei Zhou, Clement Ma, Wei Xu, Ariela L. Marshall, Rihong Zhai, Susanne M. Hooshmand, Kofi Asomaning, Li Su, Frances A. Shepherd, Thomas J. Lynch, John C. Wain, David C. Christiani, Geoffrey Liu. (2009) Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenetics and Genomics 19:8, 613-625
CrossRef256
Y. Koh, T. M. Kim, Y. K. Jeon, T.-K. Kwon, J. H. Hah, S.-H. Lee, D.-W. Kim, H.-G. Wu, C.-S. Rhee, M.-W. Sung, C. W. Kim, K. H. Kim, D. S. Heo. (2009) Class III -tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Annals of Oncology 20:8, 1414-1419
CrossRef257
Navneet Singh, Ashutosh N. Aggarwal. (2009) ERCC1 and RRM1 Expression in Nonsmall Cell Lung Cancer—The Good, the Bad and the Unknown. Journal of Thoracic Oncology 4:8, 1042-1043
CrossRef258
K. Okoshi, S. Nagayama, M. Furu, Y. Mori, A. Yoshizawa, J. Toguchida, Y. Sakai. (2009) A Case Report of Pathologically Complete Response of a Huge Rectal Cancer after Systemic Chemotherapy with mFOLFOX6. Japanese Journal of Clinical Oncology 39:8, 528-533
CrossRef259
Karina Dahl Steffensen, Marianne Waldstrøm, Anders Jakobsen. (2009) The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer 19:5, 820-825
CrossRef260
Ana Belén Custodio, José Luis González-Larriba, Jana Bobokova, Antonio Calles, Rafael Álvarez, Eugenio Cuadrado, Aranzazu Manzano, Eduardo Díaz-Rubio. (2009) Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:7, 891-910
CrossRef261
Young Hak Kim, Genichiro Ishii, Koichi Goto, Shuji Ota, Kaoru Kubota, Yukinori Murata, Michiaki Mishima, Nagahiro Saijo, Yutaka Nishiwaki, Atsushi Ochiai. (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:1, 105-111
CrossRef262
Koichi Azuma, Tetsuro Sasada, Akihiko Kawahara, Satoshi Hattori, Takashi Kinoshita, Sinzo Takamori, Masao Ichiki, Youhei Imamura, Jiro Ikeda, Masayoshi Kage, Michihiko Kuwano, Hisamichi Aizawa. (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemotherapy and Pharmacology 64:3, 565-573
CrossRef263
B. Burtness, M. Gibson, B. Egleston, R. Mehra, L. Thomas, R. Sipples, M. Quintanilla, J. Lacy, S. Watkins, J. R. Murren, A. A. Forastiere. (2009) Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of Oncology 20:7, 1242-1248
CrossRef264
Miriam Koopman, Sabine Venderbosch, Iris D. Nagtegaal, Johan H. van Krieken, Cornelis J. Punt. (2009) A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. European Journal of Cancer 45:11, 1935-1949
CrossRef265
D. Planchard, J. Domont, E. Taranchon, I. Monnet, J. Tredaniel, R. Caliandro, P. Validire, B. Besse, J.-C. Soria, P. Fouret. (2009) The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Annals of Oncology 20:7, 1257-1263
CrossRef266
Aubrey Jolly Graham, Anil Potti. (2009) Translating genomics into clinical practice: Applications in lung cancer. Current Oncology Reports 11:4, 263-268
CrossRef267
Lina Carvalho, António Silva, Cláudia Andrade, Cláudia Barroso, Cláudia Farinha, José Carlos Fernandes, Raquel Landeiro. (2009) Os genes ERCC1 e RRM1 no carcinoma broncopulmonar. Revista Portuguesa de Pneumologia (English Edition) 15:4, 683-696
CrossRef268
Yoshitaka Tomoda, Mari Katsura, Miyuki Okajima, Noriko Hosoya, Nobuoki Kohno, Kiyoshi Miyagawa. (2009) Functional evidence for Eme1 as a marker of cisplatin resistance. International Journal of Cancer 124:12, 2997-3001
CrossRef269
Koichi Azuma, Tetsuro Sasada, Akihiko Kawahara, Sinzo Takamori, Satoshi Hattori, Jiro Ikeda, Kyogo Itoh, Akira Yamada, Masayoshi Kage, Michihiko Kuwano, Hisamichi Aizawa. (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:3, 326-333
CrossRef270
Dan Su, Stephanie M. Smith, Mario Preti, Peter Schwartz, Thomas J. Rutherford, Guido Menato, Saverio Danese, Shenglin Ma, Herbert Yu, Dionyssios Katsaros. (2009) Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 115:11, 2453-2463
CrossRef271
Paul Van Houtte. (2009) Lung cancer: from staging to treatment – a summary of an international meeting. Expert Review of Respiratory Medicine 3:3, 221-225
CrossRef272
Valentina Monica, Paolo Ceppi, Luisella Righi, Veronica Tavaglione, Marco Volante, Giuseppe Pelosi, Giorgio V Scagliotti, Mauro Papotti. (2009) Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Modern Pathology 22:5, 709-717
CrossRef273
Xiaobing Chen, Suxia Luo, Ning Li, Yongping Song, Junjie Zen. (2009) Relationship between the expression of ERCC-1, survivin and both efficiency and prognosis of cisplatin contained first-line chemotherapy in advanced lung adenocarcinoma. The Chinese-German Journal of Clinical Oncology 8:5, 265-268
CrossRef274
Romano Danesi, Giuseppe Pasqualetti, Elisa Giovannetti, Francesco Crea, Giuseppe Altavilla, Mario Del Tacca, Rafael Rosell. (2009) Pharmacogenomics in non-small-cell lung cancer chemotherapy. Advanced Drug Delivery Reviews 61:5, 408-417
CrossRef275
Neal Navani, Stephen G. Spiro, Sam M. Janes. (2009) Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound. Nature Reviews Clinical Oncology 6:5, 278-286
CrossRef276
Adam Vilmar, Jens Benn Sørensen. (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer 64:2, 131-139
CrossRef277
R D Riley, W Sauerbrei, D G Altman. (2009) Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. British Journal of Cancer 100:8, 1219-1229
CrossRef278
Shuji Ota, Genichiro Ishii, Koichi Goto, Kaoru Kubota, Young Hak Kim, Masakazu Kojika, Yukinori Murata, Manabu Yamazaki, Yutaka Nishiwaki, Kenji Eguchi, Atsushi Ochiai. (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64:1, 98-104
CrossRef279
Pere Gascón. (2009) Futuro de los marcadores moleculares en cáncer: hacia un tratamiento personalizado. Medicina Clínica 132:14, 549-550
CrossRef280
J-S Kim, M-A Kim, T M Kim, S-H Lee, D-W Kim, S-A Im, T-Y Kim, W H Kim, H-K Yang, D S Heo, Y-J Bang, K-U Lee, K-J Choe, N K Kim. (2009) Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. British Journal of Cancer 100:5, 732-738
CrossRef281
Britta Stordal, Ross Davey. (2009) ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer Chemotherapy and Pharmacology 63:4, 661-672
CrossRef282
L. Gossage, M. Mohammed, S. Madhusudan. (2009) Clinical implications of DNA repair genetic alterations in cancer. memo - Magazine of European Medical Oncology 2:1, 15-19
CrossRef283
Rossana Berardi, Lorena Verdecchia, Marzia Di Pietro Paolo, Riccardo Giampieri, Mario Scartozzi, Chiara Pierantoni, Maristella Bianconi, Paola Mazzanti, Stefano Cascinu. (2009) Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology 69:3, 223-236
CrossRef284
Tanya B. Dorff, Denice Tsao-Wei, Gus Miranda, Donald G. Skinner, John P. Stein, David I. Quinn. (2009) Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World Journal of Urology 27:1, 39-44
CrossRef285
Hidefumi Sasaki, Katsuhiro Okuda, Shigeki Shimizu, Minoru Takada, Masaaki Kawahara, Naoto Kitahara, Meinoshin Okumura, Akihide Matsumura, Keiji Iuchi, Tomoya Kawaguchi, Akihito Kubo, Osamu Kawano, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii. (2009) EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. Journal of Cancer Research and Clinical Oncology 135:2, 313-318
CrossRef286
Hossein Borghaei, Ranee Mehra, George Simon. (2009) Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. Future Oncology 5:1, 19-22
CrossRef287
Neel Shah, Don S Dizon. (2009) New-generation platinum agents for solid tumors. Future Oncology 5:1, 33-42
CrossRef288
Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Po-Min Chen, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Wei-Shu Wang. (2009) ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Science 100:2, 278-283
CrossRef289
Sung-Hyun Kim, Hyuk-Chan Kwon, Sung Yong Oh, Dong Mee Lee, Suee Lee, Jong-Hoon Lee, Mee-Sook Roh, Dae-Cheol Kim, Ki-Jae Park, Hong-Jo Choi, Hyo-Jin Kim. (2009) Prognostic Value of ERCC1, Thymidylate Synthase, and Glutathione S-Transferase π for 5-FU/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer. American Journal of Clinical Oncology 32:1, 38-43
CrossRef290
George Fountzilas, Anna Kalogera-Fountzila, Sophia Lambaki, Ralph M. Wirtz, Angelos Nikolaou, Georgia Karayannopoulou, Mattheos Bobos, Vassiliki Kotoula, Samuel Murray, Alexandros Lambropoulos, Gerasimos Aravantinos, Konstantinos Markou, Eleni Athanassiou, Despina Misailidou, Konstantine T. Kalogeras, Demosthenis Skarlos. (2009) MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology 2009, 1-17
CrossRef291
Romano Danesi, Giuseppe Altavilla, Elisa Giovannetti, Raffael Rosell. (2009) Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics 10:1, 69-80
CrossRef292
Sylvie Lantuéjoul, Dimitri Salameire, Caroline Salon, Elisabeth Brambilla. (2009) Pulmonary preneoplasia - sequential molecular carcinogenetic events. Histopathology 54:1, 43-54
CrossRef293
V. Surmont, J. G. J. V. Aerts, K. Y. Tan, F. Schramel, R. Vernhout, H. C. Hoogsteden, R. J. van Klaveren. (2009) Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. Journal of Oncology 2009, 1-6
CrossRef294
Sarah A Martin, Madeleine Hewish, Christopher J Lord, Alan Ashworth. (2009) Genomic instability and the selection of treatments for cancer. The Journal of Pathologyn/a-n/a
CrossRef295
Stefan Landgraeber, Marius von Knoch, Franz Löer, Alexander Wegner, Michael Tsokos, Kurt Werner Schmid, Martin Totsch. (2009) ERCC1 expression in aseptic loosening after total hip replacement. Journal of Biomedical Materials Research Part A 9999A, NA-NA
CrossRef296
Andrew H. Ko, Margaret A. Tempero. (2009) Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction. Gastroenterology 136:1, 43-45
CrossRef297
Fred R. Hirsch, Anna Spreafico, Silvia Novello, Mary Dugan Wood, Lorinda Simms, Mauro Papotti. (2008) The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:12, 1468-1481
CrossRef298
Chiun Hsu, Sung-Hsin Kuo, Fu-Chang Hu, Ann-Lii Cheng, Jin-Yuan Shih, Chong-Jen Yu, Chia-Chi Lin, Tsu-Chen Huang, Pan-Chyr Yang, Chih-Hsin Yang. (2008) Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial. Lung Cancer 62:3, 334-343
CrossRef299
A.-C. Hoffmann, M. Schuler. (2008) Biomarker in der Onkologie. best practice onkologie 3:6, 48-58
CrossRef300
Fabrice Barlesi. (2008) Lung cancer: moving forward with tailored strategies. The Lancet Oncology 9:12, 1116-1117
CrossRef301
Geoffrey Y Ku, David H Ilson. (2008) Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy 8:12, 1953-1964
CrossRef302
April Scott, Ravi Salgia. (2008) Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomarkers in Medicine 2:6, 577-586
CrossRef303
H Allgayer, S Fulda. (2008) An introduction to molecular targeted therapy of cancer. Advances in Medical Sciences 53:2, 130-138
CrossRef304
George R. Simon. (2008) Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions. Current Treatment Options in Oncology 9:4-6, 300-312
CrossRef305
Edgardo S Santos, Aurelio Castrellon, Marcelo Blaya, Luis E Raez. (2008) Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:12, 1913-1929
CrossRef306
Y. Auclair, R. Rouget, E. B. Affar, E. A. Drobetsky. (2008) ATR kinase is required for global genomic nucleotide excision repair exclusively during S phase in human cells. Proceedings of the National Academy of Sciences 105:46, 17896-17901
CrossRef307
Giuseppe Aprile, Ornella Belvedere, Fabio Puglisi. (2008) From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. Anti-Cancer Drugs 19:10, 941-956
CrossRef308
Chiara Arienti, Anna Tesei, Alberto Ravaioli, Marina Ratta, Silvia Carloni, Serena Mangianti, Paola Ulivi, Stefania Nicoletti, Dino Amadori, Wainer Zoli. (2008) Activity of lipoplatin in tumor and in normal cells in vitro. Anti-Cancer Drugs 19:10, 983-990
CrossRef309
Xifeng Wu, Charles Lu, Yuanqing Ye, Joe Chang, Hushan Yang, Jie Lin, Jian Gu, Waun Ki Hong, David Stewart, Margaret R. Spitz. (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics 18:11, 955-965
CrossRef310
Shilpen Patel, Rachel E. Sanborn, Charles R. Thomas. (2008) Definitive Chemoradiotherapy for Non–Small Cell Lung Cancer with N2 Disease. Thoracic Surgery Clinics 18:4, 393-401
CrossRef311
Rachel E. Sanborn, Brian E. Lally. (2008) Adjuvant Therapy for Non–Small Cell Lung Cancer with Mediastinal Nodal Involvement. Thoracic Surgery Clinics 18:4, 423-435
CrossRef312
Matthew E. Nielsen. (2008) Neoadjuvant gemcitabine and cisplatin: Another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer. Cancer 113:9, 2379-2381
CrossRef313
Chien-Gang Hsu, Long-Yau Lin, Jiunn-Liang Ko, Shun-Fa Yang, Han Chang, Ching-Yi Lin, Hsiu-Ting Tsai, Shiuan-Chih Chen, Shu-Chen Chen, Po-Hui Wang. (2008) High expression of human nonmetastatic clone 23 type 1 in cancer of uterine cervix and its association with poor cell differentiation and worse overall survival. Journal of Surgical Oncology 98:6, 448-456
CrossRef314
Nagahiro Saijo. (2008) Advances in the treatment of non-small cell lung cancer. Cancer Treatment Reviews 34:6, 521-526
CrossRef315
R. Danesi, A. Di Paolo, G. Bocci, F. Crea, M. Del Tacca. (2008) Pharmacogenetics in oncology. European Journal of Cancer Supplements 6:14, 74-78
CrossRef316
Angelo Sidoni, Fabio Cartaginese, Mariantonietta Colozza, Stefania Gori, Lucio Crinó. (2008) ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Research and Treatment 111:3, 569-570
CrossRef317
Gerold Bepler, K Eric Sommers, Alan Cantor, Xueli Li, Anupama Sharma, Charles Williams, Alberto Chiappori, Eric Haura, Scott Antonia, Tawee Tanvetyanon, George Simon, Coleman Obasaju, Lary A. Robinson. (2008) Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1112-1118
CrossRef318
Katsuhiro Okuda, Hidefumi Sasaki, Charles Dumontet, Osamu Kawano, Haruhiro Yukiue, Tomoki Yokoyama, Motoki Yano, Yoshitaka Fujii. (2008) Expression of excision repair cross-complementation group 1 and class III β-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62:1, 105-112
CrossRef319
Herbst, Roy S., Heymach, John V., Lippman, Scott M., . (2008) Lung Cancer. New England Journal of Medicine 359:13, 1367-1380
Full Text320
In Gyu Hwang, Myung Ju Ahn, Byeong Bae Park, Yong Chan Ahn, Joungho Han, Seungkoo Lee, Jhingook Kim, Young Mog Shim, Jin Seok Ahn, Keunchil Park. (2008) ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:6, 1379-1386
CrossRef321
Tina Cheng. (2008) Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. Current Opinion in Supportive and Palliative Care 2:3, 153-160
CrossRef322
Heather Wakelee, Laveena Chhatwani. (2008) Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 20:3, 198-203
CrossRef323
Ana Belén Custodio Carretero, José Ángel García Sáenz, José Luis González Larriba, Jana Bobokova, Antonio Calles Blanco, Florentino Hernando Trancho, Beatriz García Paredes, Laura Rodríguez Lajusticia, Eduardo Díaz-Rubio García. (2008) Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clinical and Translational Oncology 10:9, 560-571
CrossRef324
V. Westeel, Denis Moro-Sibilot. (2008) Prise en charge oncologique du patient opéré: chimiothérapie adjuvante, surveillance, traitement des rechutes. Oncologie 10:9, 525-528
CrossRef325
Miguel Angel Pavón, Matilde Parreño, Xavier León, Francesc J. Sancho, Maria Virtudes Céspedes, Isolda Casanova, Antonio Lopez‐Pousa, Maria Antonia Mangues, Miquel Quer, Agustí Barnadas, Ramón Mangues. (2008) Ku 70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. International Journal of Cancer 123:5, 1068-1079
CrossRef326
Justin Stebbing. (2008) FLEX data, KRAS and ERCC1 testing in oncology. Future Oncology 4:4, 471-473
CrossRef327
Ricardo L.M. Duarte, Ronir R. Luiz, Marcos E.M. Paschoal. (2008) The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients. Lung Cancer 61:2, 244-254
CrossRef328
Ramaswamy Govindan, Jeffrey Bogart, Everett E. Vokes. (2008) Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future. Journal of Thoracic Oncology 3:8, 917-928
CrossRef329
Ji‐Youn Han, Dae Ho Lee, Jung Eun Song, Sung Young Lee, Hyae Young Kim, Heung Tae Kim, Jin Soo Lee. (2008) Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer. Cancer 113:2, 388-395
CrossRef330
N Tajeddine, L Galluzzi, O Kepp, E Hangen, E Morselli, L Senovilla, N Araujo, G Pinna, N Larochette, N Zamzami, N Modjtahedi, A Harel-Bellan, G Kroemer. (2008) Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 27:30, 4221-4232
CrossRef331
H J Jun, M J Ahn, H S Kim, S Y Yi, J Han, S K Lee, Y C Ahn, H-S Jeong, Y-I Son, J-H Baek, K Park. (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. British Journal of Cancer 99:1, 167-172
CrossRef332
K.D. STEFFENSEN, M. WALDSTRM, U. JEPPESEN, I. BRANDSLUND, A. JAKOBSEN. (2008) Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. International Journal of Gynecological Cancer 18:4, 702-710
CrossRef333
Joshua J Filner, David Ost. (2008) Principles of staging as applied to nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine 14:4, 287-291
CrossRef334
C. M. Raynaud, S. J. Jang, P. Nuciforo, S. Lantuejoul, E. Brambilla, N. Mounier, K. A. Olaussen, F. Andre, L. Morat, L. Sabatier, J.-C. Soria. (2008) Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Annals of Oncology 19:11, 1875-1881
CrossRef335
Zhong Zheng, Xueli Li, Michael J. Schell, Tingan Chen, David Boulware, Lary Robinson, Eric Sommers, Gerold Bepler. (2008) Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 112:12, 2765-2773
CrossRef336
Kyung-Hun Lee, Hye Sook Min, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Young Tae Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Sook Whan Sung, Joo Hyun Kim. (2008) ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60:3, 401-407
CrossRef337
Richard L Schilsky. (2008) How not to treat cancer. The Lancet Oncology 9:6, 504-505
CrossRef338
Junichi SHIMIZU, Yoshitsugu HORIO, Hirotaka OSADA, Toyoaki HIDA, Yoshinori HASEGAWA, Kaoru SHIMOKATA, Takashi TAKAHASHI, Yoshitaka SEKIDO, Yasushi YATABE. (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13:4, 510-517
CrossRef339
A. Zabernigg. (2008) New developments in lung cancer in 2007. memo - Magazine of European Medical Oncology 1:S3, 20-23
CrossRef340
Felix J.F. Herth, Ross K. Morgan, Ralf Eberhardt, Armin Ernst. (2008) Endobronchial Ultrasound-Guided Miniforceps Biopsy in the Biopsy of Subcarinal Masses in Patients with Low Likelihood of Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 85:6, 1874-1878
CrossRef341
Nanae Tomonaga, Yoichi Nakamura, Hiroshi Soda, Seiji Nagashima, Hirofumi Nakano, Akitoshi Kinoshita, Masaaki Fukuda, Minoru Fukuda, Hiroshi Takatani, Yoshifumi Soejima, Mikio Oka, Shigeru Kohno, . (2008) Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 62:1, 43-49
CrossRef342
Kevin T. Palka, Robbert J. Slebos, Christine H. Chung. (2008) Update on Molecular Diagnostic Tests in Head and Neck Cancer. Seminars in Oncology 35:3, 198-210
CrossRef343
M. Dediu. (2008) Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?. memo - Magazine of European Medical Oncology 1:2, 61-65
CrossRef344
Paolo Ceppi, Marina Longo, Marco Volante, Silvia Novello, Susanna Cappia, Elisa Bacillo, Giovanni Selvaggi, Silvia Saviozzi, Raffaele Calogero, Mauro Papotti, Giorgio V. Scagliotti. (2008) Excision Repair Cross Complementing-1 and Topoisomerase II?? Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide. Journal of Thoracic Oncology 3:6, 583-589
CrossRef345
M. Filipits, R. Pirker. (2008) Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives. memo - Magazine of European Medical Oncology 1:2, 57-60
CrossRef346
F. J. P. Hoebers, D. Pluim, A. A. M. Hart, M. Verheij, A. J. M. Balm, G. Fons, C. R. N. Rasch, J. H. M. Schellens, L. J. A. Stalpers, H. Bartelink, A. C. Begg. (2008) Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemotherapy and Pharmacology 61:6, 1075-1081
CrossRef347
Philip C. Mack, David R. Gandara. (2008) 2008 Highlights from: The IASLC-ESMO 1st European Lung Cancer Conference; Geneva, Switzerland; April 2008. Clinical Lung Cancer 9:3, 145-147
CrossRef348
Andrew J. Vickers, Kwang Jang, Daniel Sargent, Hans Lilja, Michael W. Kattan. (2008) Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 112:8, 1862-1868
CrossRef349
Chia-Chi Lin, Chih-Hung Hsu, Yeong-Shiau Pu, Nicholas J. Vogelzang. (2008) Systemic therapy for metastatic urothelial carcinoma. BJU International 101:7, 795-803
CrossRef350
Guru Sonpavde, Robert Ross, Thomas Powles, Christopher J. Sweeney, Noah Hahn, Thomas E. Hutson, Matthew D. Galsky, Seth P. Lerner, Cora N. Sternberg. (2008) Novel agents for muscle-invasive and advanced urothelial cancer. BJU International 101:8, 937-943
CrossRef351
Mary Lowery Nordberg. (2008) Molecular Pathology—Translating Research into Clinical Practice: An Expanding Frontier in Surgical Oncology. Surgical Oncology Clinics of North America 17:2, 303-321
CrossRef352
Tetsuya Fujii, Shinichi Toyooka, Kouichi Ichimura, Yoshiro Fujiwara, Katsuyuki Hotta, Junichi Soh, Hiroshi Suehisa, Naruyuki Kobayashi, Motoi Aoe, Tadashi Yoshino, Katsuyuki Kiura, Hiroshi Date. (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:3, 377-384
CrossRef353
Thomas Helleday, Eva Petermann, Cecilia Lundin, Ben Hodgson, Ricky A. Sharma. (2008) DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 8:3, 193-204
CrossRef354
Po-Hui Wang, Jiunn-Liang Ko, Hsiu-Ting Tsai, Shun-Fa Yang, Chih-Ping Han, Long-Yau Lin, Gin-Den Chen. (2008) Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: A semiquantitative study of immunoreactivities using tissue array. Gynecologic Oncology 108:3, 533-542
CrossRef355
K Kaira, N Oriuchi, H Imai, K Shimizu, N Yanagitani, N Sunaga, T Hisada, S Tanaka, T Ishizuka, Y Kanai, H Endou, T Nakajima, M Mori. (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer. British Journal of Cancer 98:4, 742-748
CrossRef356
Per-Uno Malmström. (2008) WHY HAS THE SURVIVAL OF PATIENTS WITH BLADDER CANCER NOT IMPROVED?. BJU International 101:3, 267-269
CrossRef357
Kiyoshi Miyagawa. (2008) Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Science 99:2, 187-194
CrossRef358
George R Simon, Mubeena Begum, Gerold Bepler. (2008) Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncology 4:1, 51-59
CrossRef359
Pascal Sève, Charles Dumontet. (2008) Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?. The Lancet Oncology 9:2, 168-175
CrossRef360
Alan D. D'Andrea. 2008. DNA Repair Pathways and Human Cancer. , 39-55.
CrossRef361
Alzbeta Kracmarova, Jaroslav Cermak, Radim Brdicka, Hana Bruchova. (2008) High expression of ERCC1 , FLT1 , NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome. Leukemia & Lymphoma 49:7, 1297-1305
CrossRef362
Hiroshi Suehisa, Shinichi Toyooka, Katsuyuki Hotta, Akiko Uchida, Junichi Soh, Yoshiro Fujiwara, Keitaro Matsuo, Mamoru Ouchida, Minoru Takata, Katsuyuki Kiura, Hiroshi Date. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 120:3, 265-269
CrossRef363
N.H. Hanna. (2008) A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer. Yearbook of Medicine 2008, 180-182
CrossRef364
Sung-Liang Yu, Hsuan-Yu Chen, Gee-Chen Chang, Chih-Yi Chen, Huei-Wen Chen, Sher Singh, Chiou-Ling Cheng, Chong-Jen Yu, Yung-Chie Lee, Han-Shiang Chen, Te-Jen Su, Ching-Cheng Chiang, Han-Ni Li, Qi-Sheng Hong, Hsin-Yuan Su, Chun-Chieh Chen, Wan-Jiun Chen, Chun-Chi Liu, Wing-Kai Chan, Wei J. Chen, Ker-Chau Li, Jeremy J.W. Chen, Pan-Chyr Yang. (2008) MicroRNA Signature Predicts Survival and Relapse in Lung Cancer. Cancer Cell 13:1, 48-57
CrossRef365
Branimir I. Sikic. 2008. Natural and Acquired Resistance to Cancer Therapies. , 583-592.
CrossRef366
Christopher G. Azzoli, Bernard J. Park, William Pao, Maureen Zakowski, Mark G. Kris. (2008) Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:1, 84-93
CrossRef367
Min Kyoung Kim, Kyung-Ja Cho, Gui Young Kwon, Seung-Il Park, Yong Hee Kim, Jong Hoon Kim, Ho-Young Song, Ji Hoon Shin, Hwoon Yong Jung, Gin Hyug Lee, Kee Don Choi, Sung-Bae Kim. (2008) ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. European Journal of Cancer 44:1, 54-60
CrossRef368
Hyun Woo Lee, Jae Ho Han, Jang Hee Kim, Myoung Hee Lee, Seong Hyun Jeong, Seok Yun Kang, Jin-Hyuk Choi, Young Taek Oh, Kwang Joo Park, Sung Chul Hwang, Seung Soo Sheen, Ho-Yeong Lim. (2008) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59:1, 95-104
CrossRef369
N.H. Hanna. (2008) A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer. Yearbook of Medicine 2008, 182-184
CrossRef370
Sylvia Stadlmann, Gad Singer, Stephan Dirnhofer, Svenja Thies, Uwe Güth. (2008) ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecologic Oncology 108:1, 252-253
CrossRef371
Lynn T. Tanoue, Scott Gettinger. (2007) Treatment of Lung Cancer in Older Patients. Clinics in Chest Medicine 28:4, 735-749
CrossRef372
Sylke Nagel, Raffaele Califano, Nicholas Thatcher, Fiona Blackhall. (2007) Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opinion on Pharmacotherapy 8:18, 3265-3275
CrossRef373
Sabine Danzinger, Martin Filipits. (2007) Biomarker – der Weg zur individualisierten Chemotherapie beim nicht-kleinzelligen Bronchialkarzinom. Wiener Medizinische Wochenschrift 157:21-22, 554-561
CrossRef374
Olaussen, Ken A., , Fouret, Pierre, , Kroemer, Guido, . (2007) ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer. New England Journal of Medicine 357:15, 1559-1561
Full Text375
Sophie Sun, Joan H. Schiller, Monica Spinola, John D. Minna. (2007) New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation 117:10, 2740-2750
CrossRef376
Rebecca S Heist, Geoffrey Liu, Wei Zhou. (2007) Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?. Nature Clinical Practice Oncology 4:10, 564-565
CrossRef377
Richard Booton, Tim Ward, Linda Ashcroft, Julie Morris, Jim Heighway, Nick Thatcher. (2007) ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2:10, 902-906
CrossRef378
M. Wislez, M. Antoine, A. Lavolé, V. Gounant, B. Milleron, J. Cadranel. (2007) Prédiction de la réponse à la chimiothérapie dans les CBNPC : applications pratiques. Revue des Maladies Respiratoires 24:8, 206-210
CrossRef379
Baorui Liu, Jia Wei, Zhengyun Zou, Xiaoping Qian, Takahiro Nakamura, Wei Zhang, Yitao Ding, Jifeng Feng, Lixia Yu. (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. European Journal of Human Genetics 15:10, 1049-1053
CrossRef380
B. Milleron, V. Gounant, É. Giroux-Leprieur, A. Lavolé. (2007) La chimiothérapie postopératoire des cancers bronchiques non à petites cellules. Revue des Maladies Respiratoires 24:8, 64-68
CrossRef381
Lucy Gossage, Srinivasan Madhusudan. (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treatment Reviews 33:6, 565-577
CrossRef382
Ana Ramírez de Molina, Jacinto Sarmentero-Estrada, Cristóbal Belda-Iniesta, Miquel Tarón, Victor Ramírez de Molina, Paloma Cejas, Marcin Skrzypski, David Gallego-Ortega, Javier de Castro, Enrique Casado, Miguel Angel García-Cabezas, Jose Javier Sánchez, Manuel Nistal, Rafael Rosell, Manuel González-Barón, Juan Carlos Lacal. (2007) Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. The Lancet Oncology 8:10, 889-897
CrossRef383
Koichi Azuma, Yoshihiro Komohara, Tetsuro Sasada, Yasuhiro Terazaki, Jiro Ikeda, Tomoaki Hoshino, Kyogo Itoh, Akira Yamada, Hisamichi Aizawa. (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Science 98:9, 1336-1343
CrossRef384
Maria De Santis, Mark Bachner. (2007) New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Current Opinion in Urology 17:5, 363-368
CrossRef385
Gerold Bepler. (2007) Phase II Pharmacogenomics-Based Adjuvant Therapy Trial in Patients with Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial 0720. Clinical Lung Cancer 8:8, 509-511
CrossRef386
Tomoyoshi Takenaka, Ichiro Yoshino, Hidenori Kouso, Taro Ohba, Tomofumi Yohena, Atsushi Osoegawa, Fumihiro Shoji, Yoshihiko Maehara. (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. International Journal of Cancer 121:4, 895-900
CrossRef387
David H. Johnson. (2007) Advances in Management of NSCLC - Advances in Chemotherapy. Journal of Thoracic Oncology 2:Supplement 4, S145-S146
CrossRef388
George Simon. (2007) Pharmacogenomic applications in the management of Non-Small Cell Lung Cancer (NSCLC): from clinical trials to clinical practice. Journal of Thoracic Oncology 2:Supplement 4, S302-S304
CrossRef389
Giovanna Damia, Maurizio D’Incalci. (2007) Targeting DNA repair as a promising approach in cancer therapy. European Journal of Cancer 43:12, 1791-1801
CrossRef390
Giorgio V. Scagliotti, Paolo Ceppi, Silvia Novello. (2007) Predictive markers for adjuvant treatment. Journal of Thoracic Oncology 2:Supplement 4, S244-S245
CrossRef391
Thierry Le Chevalier. (2007) Adjuvant treatment for resectable lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S241-S242
CrossRef392
Giovanni Selvaggi, Giorgio Vittorio Scagliotti. (2007) Perspectives in adjuvant chemotherapy in NSCLC. Expert Review of Respiratory Medicine 1:1, 99-110
CrossRef393
Fred R. Hirsch, Rafal Dziadziuszko. (2007) Molecular staging of lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S143-S144
CrossRef394
Gerard A. Silvestri. (2007) A Seismic Shift in Staging. Journal of Thoracic Oncology 2:8, 682-683
CrossRef395
Rafael Rosell. (2007) The predictive and prognostic roles of ERCC1 Expression and Akin DNA repair genes in non-small-cell lung cancer. Journal of Thoracic Oncology 2:Supplement 4, S166-S167
CrossRef396
Lodovico Balducci. (2007) Molecular insight in cancer treatment and prevention. The International Journal of Biochemistry & Cell Biology 39:7-8, 1329-1336
CrossRef397
Ken André Olaussen, Giannis Mountzios, Jean-Charles Soria. (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Current Opinion in Pulmonary Medicine 13:4, 284-289
CrossRef398
Wah K. LAM, D Neil WATKINS. (2007) Lung cancer: Future directions. Respirology 12:4, 471-477
CrossRef399
Rina Ohashi, Fumiyuki Takahashi, Ri Cui, Masakata Yoshioka, Tao Gu, Shinichi Sasaki, Shigeru Tominaga, Kazuto Nishio, Kenneth K. Tanabe, Kazuhisa Takahashi. (2007) Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Letters 252:2, 225-234
CrossRef400
Christopher G. Azzoli, Lee M. Krug, Vincent A. Miller, Naiyer A. Rizvi, Mark G. Kris, Megan Dunne, Amy Farmer, Barbara Pizzo, Leslie Tyson, Teresa Seeger, Barbara Coleman, Erin Moore, Lauren Lastinger, Ennapadam Venkatraman, Charles M. Rudin. (2007) A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:7, 638-644
CrossRef401
George R. Simon, Roohi Ismail-Khan, Gerold Bepler. (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. The International Journal of Biochemistry & Cell Biology 39:7-8, 1318-1328
CrossRef402
(2007) ERCC1 and Non–Small-Cell Lung Cancer. New England Journal of Medicine 356:24, 2538-2541
Full Text403
Frances A Shepherd, Rafael Rosell. (2007) Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Suppl 2, S68-S76
CrossRef404
Emilio Bria, Federica Cuppone, Fabiana Letizia Cecere, Michele Milella, Cecilia Nisticò, Francesco Cognetti, Edmondo Terzoli. (2007) Adjuvant Chemotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S7-S11
CrossRef405
Eric Vallières. (2007) Role of Adjuvant Systemic Therapy for Stage I NSCLC. Thoracic Surgery Clinics 17:2, 279-285
CrossRef406
Romano Danesi, Giuseppe Pasqualetti, Elisa Giovannetti, Mario Del Tacca. (2007) The Role of Pharmacogenetics in Adjuvant Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:Supplement 1, S27-S30
CrossRef407
Leora Horn, Alan B. Sandler, Joe B. Putnam, David H. Johnson. (2007) The Rationale for Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:5, 377-383
CrossRef408
Enriqueta Felip, Rafael Rosell. (2007) Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Review of Molecular Diagnostics 7:3, 261-268
CrossRef409
Silvia Novello, Marina Longo, Matteo Giaj Levra. (2007) Toward Therapies Tailored to Patient Characteristics. Journal of Thoracic Oncology 2:Supplement 1, S38-S41
CrossRef410
Thomas A. d'Amato. (2007) Adjuvant Chemotherapy and the Role of Chemotherapy Resistance Testing for Stage I Non–Small Cell Lung Cancer. Thoracic Surgery Clinics 17:2, 287-299
CrossRef411
Philip Bonomi. (2007) Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 7:4, 415-422
CrossRef412
David J. Stewart, Gabriela Chiritescu, Simone Dahrouge, Srabani Banerjee, Eva M. Tomiak. (2007) Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treatment Reviews 33:2, 101-137
CrossRef413
Daniel B. Costa, Sigui Li, Olivier Kocher, Richard H. Feins, Steven M. Keller, Joan H. Schiller, David H. Johnson, Daniel G. Tenen, Balazs Halmos. (2007) Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590. Lung Cancer 56:1, 97-103
CrossRef414
Jhanelle Gray, George Simon, Gerold Bepler. (2007) Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Review of Anticancer Therapy 7:4, 545-549
CrossRef415
D. H. Johnson, V. W. Rusch, A. T. Turrisi. (2007) Scalpels, Beams, Drugs, and Dreams: Challenges of Stage IIIA-N2 Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute 99:6, 415-418
CrossRef416
Zheng, Zhong, Chen, Tingan, Li, Xueli, Haura, Eric, Sharma, Anupama, Bepler, Gerold, . (2007) DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer. New England Journal of Medicine 356:8, 800-808
Full Text417
Gazdar, Adi F., . (2007) DNA Repair and Survival in Lung Cancer — The Two Faces of Janus. New England Journal of Medicine 356:8, 771-773
Full Text418
Herbst, Roy S., Lippman, Scott M., . (2007) Molecular Signatures of Lung Cancer — Toward Personalized Therapy. New England Journal of Medicine 356:1, 76-78
Full Text419
Tatsuya Yoshimasu, Shoji Oura, Takeshi Tamaki, Fuminori Ota, Rie Nakamura, Yukio Shimizu, Yoshimitsu Hirai, Koma Naito, Megumi Kiyoi, Mitsumasa Kawago, Yoshitaka Okamura. (2007) Adjuvant chemotherapy with paclitaxel for non-small cell lung cancer. The Journal of the Japanese Associtation for Chest Surgery 21:7, 882-885
CrossRef420
Cai Li, Akihiko Gemma, Yuji Minegishi, Kuniko Matsuda, Yoko Seike, Rintaro Noro, Aki Shionoya, Akiko Kawakami, Naoki Ogawa, Shoji Kudoh. (2007) In vitro Simulation Study of Individualized Chemotherapy in Lung Cancer. Journal of Nippon Medical School 74:3, 217-222
CrossRef421
Ulrich Gatzemeier, Frank Griesinger, Rudolf M. Huber, Michael Thomas. (2007) Tumortherapie im Spannungsfeld von Pharmakoökonomie und Innovation*. Onkologie 30:1, 11-16
CrossRef422
(2006) DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer. New England Journal of Medicine 355:24, 2590-2591
Full Text423
(2006) Prognostic value of the ERCC1 protein in NSCLC. Nature Clinical Practice Oncology 3:12, 646-646
CrossRef424
Aarati Ranganathan, Alex Adjei, Primo Lara. (2006) 2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25–26, 2006. Clinical Lung Cancer 8:3, 170-178
CrossRef425
M Nazir Ibrahim, Zarina Abdullah, Michael J Martin. (2006) Recent developments in the chemotherapeutic options for nonsmall cell lung cancer. Expert Review of Anticancer Therapy 6:10, 1397-1410
CrossRef426
Reed, Eddie, . (2006) ERCC1 Measurements in Clinical Oncology. New England Journal of Medicine 355:10, 1054-1055
Full Text
- Letters
